SRAD Shareholders - Lead Plaintiff Deadline: July 17, 2026

Sportradar Group AG Class Action Lawsuit – SRAD

 

Sportradar Class Action Summary

Company

Sportradar Group AG (NASDAQ: SRAD)

Lead Plaintiff Deadline

July 17, 2026

Class Period

November 7, 2024 – April 21, 2026

Stock Drop

April 22, 2026 – SRAD fell $3.80 (22.6%) to $13.04

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Sportradar Group AG (NASDAQ: SRAD), its Founder and Chief Executive Officer Carsten Koerl, and its Chief Financial Officer Craig Felenstein on behalf of investors who purchased Sportradar Class A ordinary shares between November 7, 2024, and April 21, 2026. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements about Sportradar's legal and regulatory compliance practices, its Know-Your-Customer ("KYC") processes, and its commitment to ethical business conduct. According to the complaint, defendants concealed that Sportradar intentionally worked with black-market gambling operators across multiple countries as a core business strategy to drive revenues. When two independent research firms published reports on April 22, 2026, revealing Sportradar's extensive ties to illegal gambling operations worldwide, SRAD shares plummeted $3.80 per share, or approximately 22.6%, to close at $13.04.

Company Profile

Sportradar Group AG is a Switzerland-based provider of data platforms and services to the global sports betting industry, including data collection and processing, risk management, and fraud monitoring. The Company partners with prominent sports organizations such as the NBA, MLB, the NHL, the PGA Tour, and FIFA to supply pre-match and live data and odds to betting operators including Bet365, Caesars, DraftKings, Entain, FanDuel, and William Hill. Sportradar also distributes sports audiovisual content to media outlets and betting operators globally.

Class Period

November 7, 2024 – April 21, 2026, inclusive.

Investors who purchased or acquired Sportradar Group AG (SRAD) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that Sportradar repeatedly assured investors throughout the Class Period that the Company operated with the highest standards of ethics and integrity and maintained rigorous compliance processes to ensure it only worked with legally licensed gambling operators. Beginning with the Company's third quarter 2024 financial results filed on November 7, 2024, and continuing through its 2025 Annual Report filed on March 27, 2026, Sportradar's SEC filings, signed and certified by defendants Koerl and Felenstein, represented that the Company had "obtained necessary licenses, authorizations, findings of suitability, registrations, permits and approvals necessary for [its] current operations" and made "good faith efforts to comply with all local requirements." The Company's Code of Business Conduct and Ethics, published on its website throughout the Class Period, further emphasized that Sportradar "place[d] integrity, transparency and professionalism at the heart of all [it] do[es]."

According to the complaint, defendants actively reinforced these representations through public appearances and investor communications. On April 1, 2025, defendant Koerl appeared on CNBC's "MAD MONEY" and likened Sportradar to "the SEC or the FBI" for the gambling industry, highlighting its purported ability to police fraudulent and illicit activity. During the Company's third quarter 2025 earnings call on November 5, 2025, when a Citizens Bank analyst directly questioned Sportradar's exposure to gray and black markets, Koerl described a "four-level process" to confirm the Company "only work[s] with licensed operators," including a "global compliance team" conducting "intensive KYC with every operator" and an "internal audit" process to detect unauthorized use of Sportradar's content. Koerl characterized violations as occurring in only "a handful of cases every year" and emphasized that the Company was "monitoring this very closely."

The complaint alleges these statements were materially false and misleading because Sportradar was, in fact, intentionally working with black-market gambling operators to increase its revenues. Rather than maintaining the robust KYC and compliance infrastructure defendants described, the complaint alleges the Company employed what one investigative report later characterized as a "check-the-box" KYC review paired with a deliberate "see nothing, know nothing" approach to illegal markets. Plaintiffs allege defendants knew or recklessly disregarded that Sportradar's compliance processes were not as robust as publicly claimed and that the Company's business practices directly contradicted its stated commitment to ethics, integrity, and legal compliance.

The Truth Emerges

On April 22, 2026, two independent market research firms, Muddy Waters Research and Callisto Research, separately published investigative reports that revealed Sportradar's extensive ties to illegal gambling operations worldwide. Muddy Waters reported that its investigators had posed as sportsbook operators at the International Casinos Exhibition, a major global gaming convention, where a Sportradar sales executive allegedly "bragged that [Sportradar] 'serves everyone'" and walked the investigators through product offerings for illegal markets in Vietnam, Thailand, Indonesia, and China. The executive purportedly listed major business-to-business clients in Asia that were known illegal operators and offered to facilitate introductions, including to the Yabo Group, a notorious illegal betting operation in China associated with human trafficking, modern slavery, kidnapping, and torture at Cambodian customer service centers. Muddy Waters further identified connections between Sportradar and illegal operators in Russia, Turkey, and multiple Asian markets, concluding that Sportradar "has actively aided and abetted illegal gambling across the world's black and grey markets, not as an accident or an oversight, but as a business strategy."

Callisto Research's separate investigation examined hundreds of gambling platforms and found evidence suggesting that over 270 individual platforms, representing more than a third of the approximately 800 operators Sportradar claimed to serve, were using Sportradar's products or services while operating illegally in regulated or prohibited gambling markets. Former Sportradar employees told Callisto that one of the Company's top ten clients, 1xBet, was "likely to be the world's largest illegal gambling operator by revenue." Callisto also reported that it had shared its findings with multiple regulators in North America and Europe, three of which had already commenced reviews of Sportradar. These revelations directly contradicted defendant Koerl's November 2025 assurances of a rigorous four-level compliance process and his characterization of compliance violations as merely a "handful of cases every year."

Market Reaction

Following the publication of the Muddy Waters and Callisto reports on April 22, 2026, SRAD shares suffered a severe single-day decline. The stock fell $3.80 per share, or approximately 22.6%, from a closing price of $16.84 on April 21, 2026, to close at $13.04 on April 22, 2026. The complaint alleges that the decline was caused by the revelations in the investigative reports, which disclosed Sportradar's ties to illegal gambling operations and noted that multiple regulators had reportedly already commenced reviews of the Company based on those findings.

Next Steps

●       Lead Plaintiff Deadline: July 17, 2026

●       After the lead-plaintiff deadline, the Court will consider any motions for appointment of lead plaintiff and lead counsel.

●       The Court may then consider a motion for class certification.

●       The case may later involve a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Sportradar Group AG which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Sportradar Group AG. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
CVLT Shareholders - Lead Plaintiff Deadline: July 17, 2026

Commvault Lawsuit Submission Form

Commvault Class Action Summary

Company

Commvault Systems, Inc. (NASDAQ: CVLT)

Lead Plaintiff Deadline

July 17, 2026

Class Period

April 29, 2025 – January 26, 2026

Stock Drop

January 27, 2026 – CVLT fell $40.23 (over 31%) to $89.13

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Commvault Systems, Inc. (NASDAQ: CVLT), its CEO Sanjay Mirchandani, and former CFO Jennifer DiRico in the United States District Court for the District of New Jersey. The lawsuit, filed by Levi & Korsinsky, LLP on behalf of plaintiff Enrique Imbert, covers investors who purchased or acquired Commvault securities between April 29, 2025 and January 26, 2026. The complaint alleges that defendants made materially false and misleading statements regarding the Company's projected annualized recurring revenue (ARR) growth for fiscal year 2026, failing to disclose that the Company's ARR guidance did not properly account for how variations in sale type, particularly the growing mix of SaaS deals versus term-license deals, would suppress net new ARR figures. When Commvault reported third quarter fiscal 2026 results on January 27, 2026, revealing net new ARR of $39 million versus the guided $45 million, the Company's stock price fell from $129.36 to $89.13 per share, a decline of over 31% in a single trading day.

Company Profile

Commvault Systems, Inc. is a data protection company that provides cyber resilience solutions and management software, specializing in hybrid and multi-cloud environments. The Company's common stock trades on the NASDAQ under the ticker symbol CVLT, and its principal offices are located in Tinton Falls, New Jersey.

Class Period

April 29, 2025 – January 26, 2026, inclusive.

Investors who purchased or acquired Commvault Systems, Inc. (CVLT) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

CVLT-Infographic-Image.png

Allegations

The complaint alleges that throughout fiscal year 2026, defendants established and repeatedly raised ARR growth guidance while knowing or recklessly disregarding that the Company's projections failed to properly account for the impact that different sale types would have on net new ARR. According to the complaint, defendants used quarterly earnings calls to paint an increasingly optimistic picture of the Company's ARR growth trajectory, creating a false impression that growth would remain steady throughout fiscal year 2026, without disclosing the fundamental vulnerability in their projections.

The alleged misstatements began on April 29, 2025, when Defendant DiRico announced initial fiscal year 2026 guidance projecting total ARR growth of 16% to 17% year-over-year during the fourth quarter and full year 2025 earnings call. On July 29, 2025, DiRico raised that guidance to 18% total ARR growth and specifically told analysts to expect "around $40 million total net new ARR quarter-over-quarter for the remaining of the year." On October 28, 2025, during the second quarter fiscal 2026 earnings call, DiRico raised guidance again to 18% to 19% total ARR growth and stated that the back half of the year implied $45 million of net new ARR on a constant currency basis, explicitly above the $40 million baseline she had set earlier in the year.

The complaint alleges that defendants knew or recklessly disregarded that SaaS deals, which were becoming an increasing proportion of Commvault's sales mix, carry significantly lower average selling prices (ASPs), typically two to three times smaller than term-license deals, meaning that a shift toward SaaS would inherently suppress net new ARR figures. The complaint alleges that, despite knowing or recklessly disregarding this sales-mix issue, defendants repeatedly raised ARR projections, creating an artificial impression of steady, accelerating growth that the complaint says was not supported by the Company’s actual business trajectory.

The Truth Emerges

On January 27, 2026, Commvault published third quarter fiscal 2026 results revealing that total net new ARR came in at $39 million on a constant currency basis, falling short of the $45 million guidance defendants had provided during the prior quarter's earnings call. During the earnings call, Danielle Abrahamsen, Commvault's Chief Accounting Officer who had assumed financial reporting responsibilities after DiRico's December 2025 departure, disclosed that 70% of the quarter's net new ARR was driven by SaaS deals, up from 61% the prior quarter. When pressed by analysts on the delta between the $45 million projection and the $39 million result, Defendant Mirchandani attributed the shortfall to the volume of SaaS land deals and software land deals in the quarter, acknowledging that "there will be variation quarter-to-quarter" based on sale type.

Analysts expressed skepticism that the explanations fully accounted for the miss. DA Davidson noted that SaaS net new ARR actually came in slightly ahead of expectations at $27.1 million, meaning the shortfall was concentrated in term-license deals, and concluded that the Company's explanations "do not seem to have been enough for investors, who by & large are still concluding there must have been some other deals that pushed or were otherwise lost." CFRA downgraded Commvault to Hold from Buy and lowered its price target to $101 from $172, while Mizuho reduced its target to $140 from $180, characterizing the quarter as "underwhelming."

Market Reaction

The market's response to Commvault's third quarter fiscal 2026 disclosure was immediate and severe. On January 27, 2026, CVLT shares fell from a closing price of $129.36 on January 26, 2026 to $89.13 per share, a decline of over 31% in a single trading day. The complaint alleges that the decline followed the gap between Commvault’s prior ARR guidance and the results disclosed on January 27, 2026, along with analyst skepticism regarding management’s explanation.

Next Steps

●        Lead Plaintiff Deadline: July 17, 2026

●        After the lead-plaintiff deadline, the Court will consider any motions for appointment of lead plaintiff and lead counsel.

●        The Court may then consider a motion for class certification.

●        The case may later involve a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Commvault Systems, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Commvault Systems, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Regeneron Pharmaceuticals, Inc. Class Action Lawsuit: REGN Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) concerning potential violations of the federal securities laws.

In March, the Senior Vice President of Investor Relations, Ryan Crowe, told investors management was “hopeful” for the LAG-3 study to show positive differentiators for Fianlimab in combination with Libtayo, such as a low to mid-teens median PFS” and an “opportunity to have … a statistically significant, clinically meaningful benefit on OS.” A little more than two months later, on May 16, 2026, Regeneron disclosed that fianlimab + Libtayo did not meet the trial's primary endpoint against Keytruda. The upbeat language on potential outcomes offered on March 10, 2026 failed to stress the risk of the trial failure. The stock fell sharply on the revelation.

If you suffered a loss on your Regeneron Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Regeneron Pharmaceuticals, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Regeneron Pharmaceuticals, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Biogen Inc. Class Action Lawsuit: BIIB Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. (NASDAQ: BIIB) concerning potential violations of the federal securities laws.

The stock fell sharply on heavy volume following the May 14 topline data release. Biogen had previously signaled confidence in its pipeline during its Q1 2025 earnings call, with management stating they expected to see data from BIIB080 in early Alzheimer's disease sometime around mid-year." The CELIA trial did not achieve statistical significance on its primary endpoint. The magnitude of the single-session decline reflected the market's reassessment of Biogen's near-term pipeline value.

If you suffered a loss on your Biogen Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Biogen Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Biogen Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Prestige Consumer Healthcare Inc. Class Action Lawsuit: PBH Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. (NYSE: PBH) concerning potential violations of the federal securities laws.

During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4. Management further projected projected free cash flow of $245 million or more for the full year alongside an adjusted EPS of $4.54. When Q4 results were reported, adjusted gross margin came in at approximately 55.4%, full-year free cash flow totaled $228 million, and adjusted diluted EPS was only 4.38; all three missed Prestige’s internal projections. Separately, Prestige Consumer Healthcare completed a $150 million acquisition of Australian skin-care firm LaCorium during the period. The acquisition was not discussed on the Q3 earnings call and was absent from the forward guidance framework presented to investors. PBH shares declined sharply following the Q4 disclosure.

If you suffered a loss on your Prestige Consumer Healthcare Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Prestige Consumer Healthcare Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Prestige Consumer Healthcare Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
PHR Shareholders - Lead Plaintiff Deadline: July 13, 2026

Phreesia, Inc. Class Action Lawsuit – PHR

Phreesia Class Action Summary

Company

Phreesia, Inc. (NYSE: PHR)

Lead Plaintiff Deadline

July 13, 2026

Class Period

May 8, 2025 – March 30, 2026

Stock Drop

March 31, 2026 – PHR fell approximately $3.03 (approximately 27%) to $8.38

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR), its Chief Executive Officer Chaim Indig, and its Chief Financial Officer Balaji Gandhi on behalf of investors who purchased Phreesia common stock between May 8, 2025, and March 30, 2026. The complaint, filed in the United States District Court for the District of Delaware by plaintiff Michael Theodoulou through the law firms Farnan LLP and Levi & Korsinsky LLP, alleges that defendants made materially false and misleading statements about Phreesia's growth trajectory and revenue outlook for fiscal year 2027, particularly regarding the strength and durability of pharmaceutical marketing commitments within its Network Solutions segment. According to the complaint, the truth emerged on March 30, 2026, when Phreesia significantly reduced its fiscal year 2027 revenue guidance, attributing the shortfall to worsening visibility and weaker pharmaceutical marketing commitments. Phreesia's stock price declined approximately 27%, falling from $11.41 to $8.38 per share, causing significant losses to investors who had purchased shares at artificially inflated prices during the Class Period.

Company Profile

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The Company's platform offers solutions including appointment optimization, referral management, AI-enabled workflows, digital check-in, clinical and administrative data capture, patient payment processing, and analytics, and it operates a Network Solutions segment through which, according to the complaint, pharmaceutical and life sciences companies direct marketing spending to reach patients across Phreesia's provider network.

Class Period

May 8, 2025 – March 30, 2026, inclusive.

Investors who purchased or acquired Phreesia, Inc. (PHR) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

PHR-Infographic-Image.png

Allegations

The complaint alleges that throughout the Class Period, defendants provided investors with an overwhelmingly positive portrayal of Phreesia's growth potential, repeatedly emphasizing the Company's ability to achieve its fiscal year 2027 revenue targets through continued expansion of its Network Solutions segment and contributions from its acquisition of AccessOne Parent Holdings, Inc. Defendants characterized pharmaceutical marketing commitments as a durable growth driver and consistently maintained or raised revenue and profitability guidance, while the complaint alleges they knew or recklessly disregarded that demand was slowing and visibility into key revenue streams was deteriorating.

On May 28, 2025, defendants published first quarter fiscal year 2026 results and maintained revenue guidance of $472 million to $482 million. During the accompanying earnings call, Defendant Gandhi told analysts that the Company's visibility into the year was "the same as it was last year at this time" and that there was nothing unusual to call out regarding Network Solutions performance. Defendant Indig described the fiscal year as "off to a strong start" and emphasized the Company's strong ROI and growing scale as reasons pharmaceutical clients would continue directing marketing dollars to Phreesia's platform. On September 4, 2025, defendants again reaffirmed revenue guidance while announcing the AccessOne acquisition and reporting a 25% growth rate in Network Solutions. Gandhi told analysts the Company was "in a similar place we were last year at this time" regarding the selling season and that the team was "performing really well," expressing confidence in the segment's trajectory. Indig highlighted emerging products including VoiceAI and HCP marketing as new growth levers, telling investors the Company was "positioning us well for the future."

On December 8, 2025, defendants narrowed and raised their fiscal year 2026 revenue outlook to $479 million to $481 million and introduced fiscal year 2027 revenue guidance of $545 million to $559 million, representing a 14-16% increase. Gandhi reiterated that Network Solutions would be the fastest-growing segment and highlighted expected contributions from new products including post-script engagement and HCP marketing. Indig described these emerging products as enabling Phreesia "to sustain growth and enhance stakeholder value" and positioned the Company's HCP marketing capabilities as a "multibillion-dollar" opportunity.

The complaint alleges these statements were materially false and misleading because defendants created the false impression that they possessed reliable information supporting the Company's long-term growth outlook while minimizing risks from slowing demand and reduced visibility in its Network Solutions segment. According to the complaint, Phreesia's portrayal of pharmaceutical marketing commitments as a durable growth driver was uncertain, putting the fiscal year 2027 revenue target at risk. The Individual Defendants, by virtue of their positions as CEO and CFO, had actual knowledge of or access to non-public information concerning the Company's slowing demand in Network Solutions, yet repeatedly and affirmatively represented that the segment's expansion would drive revenue growth and overall profitability.

The Truth Emerges

After the market closed on March 30, 2026, Phreesia announced its fourth quarter and full fiscal year 2026 results and significantly lowered its fiscal year 2027 revenue guidance to a range of $510 million to $520 million, down from the prior range of $545 million to $559 million. The Company disclosed that Network Solutions clients were committing lower spend levels for the second half of fiscal year 2027 than defendants had anticipated in December, citing worsening visibility into pharmaceutical manufacturer spending commitments and brand-specific dynamics including the impact of regulatory policies. Defendant Indig acknowledged that "segments of the life sciences industry are facing challenges" and that this was creating "more variability" in the Company's financial forecasting, while Gandhi described the booking environment as "very fluid" and identified specific areas of weakness including vaccines and public health agency spending.

As alleged in the complaint, the disclosures stood in direct contrast to the confidence defendants had expressed throughout the Class Period. Analysts reacted sharply: Truist Securities cut its price target from $24 to $11, noting the guidance reduction was "a surprising magnitude of change given that the company previously characterized their preliminary outlook as a 'conservative' starting point." J.P. Morgan lowered its target from $24 to $16 and downgraded the stock to Neutral, citing "worsening visibility into pharma DTC budgets." Citizens downgraded Phreesia to Market Perform, questioning the Company's ecosystem thesis and noting that "the company is also losing visibility into Network Solutions, which has been the fastest-growing revenue line in recent years."

Market Reaction

Following the March 30, 2026 disclosure, Phreesia's stock price declined from a closing price of $11.41 per share on March 30, 2026, to $8.38 per share on March 31, 2026, a drop of approximately $3.03 per share, or about 27%. The complaint alleges that the sharp decline reflected the market rapidly repricing Phreesia's stock as the artificial inflation from defendants' prior misleading statements was removed. Multiple analysts issued downgrades and significant price target reductions, underscoring the materiality of the information defendants had previously concealed from investors.

Next Steps

●      Lead Plaintiff Deadline: July 13, 2026

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Phreesia, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Phreesia, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join TriSalus Life Sciences, Inc. Class Action Lawsuit: TLSI Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into TriSalus Life Sciences, Inc. (NASDAQ: TLSI) concerning potential violations of the federal securities laws.

TLSI reported Q1 2026 revenue of $8.9 million. Wall Street consensus had projected $9.4 million -- a shortfall of approximately $500,000, or more than 5%. The miss arrived approximately two months after CEO Mary Szela reaffirmed full-year 2026 revenue guidance of $60 million to $62 million on the Q4 2025 earnings call on March 5, 2026. Alongside the Q1 miss, the company cut its full-year 2026 revenue outlook to $54 million to $57 million -- a reduction of up to $8 million from the range reaffirmed in March 2026. The revised midpoint of $55.5 million represented a roughly 9% reduction from the prior midpoint of $61 million.

If you suffered a loss on your TriSalus Life Sciences, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in TriSalus Life Sciences, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against TriSalus Life Sciences, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Planet Fitness, Inc. Class Action Lawsuit: PLNT Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Planet Fitness, Inc. (NYSE: PLNT) concerning potential violations of the federal securities laws.

On February 24, 2026, during Planet Fitness's Q4 2025 earnings call, CFO Jay Stasz told investors: "We expect adjusted diluted EPS to increase between 9% to 10%" for FY 2026. This is based on approximately 80 million adjusted diluted weighted average shares outstanding…and our plan to repurchase approximately $150 million worth of shares in 2026.” CEO Colleen Keating added: "Our strong 2025 performance is a direct result of our discipline and focus on our 4 strategic imperatives." The Company also guided for approximately 9% total revenue growth over 2025 and projected 150-160 equipment placements weighted toward the second half of the year. When Planet Fitness later issued weaker FY 2026 earnings expectations -- far below the 9%-10% growth range previously communicated -- management cited an extended equipment-replacement cycle, the sale of eight corporate-owned clubs in California, a $400 million debt refinancing, and weather-related disruptions affecting approximately 2,000 clubs. The true impact of these factors had not been disclosed during the February 24 call.

If you suffered a loss on your Planet Fitness, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Planet Fitness, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Planet Fitness, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
IMMP Shareholders - Lead Plaintiff Deadline: July 06, 2026

Immutep Limited Class Action Lawsuit - IMMP

 

Immutep Limited Class Action Summary

Company

Immutep Limited (NASDAQ: IMMP)

Lead Plaintiff Deadline

July 6, 2026

Class Period

March 24, 2025 – March 12, 2026

Stock Drop

March 13, 2026 – IMMP fell $2.28 (83%) to $0.48

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Immutep Limited (NASDAQ: IMMP) and three of its senior executives in the United States District Court for the Southern District of New York. The complaint, filed by plaintiff Yves Dhaenens through Levi & Korsinsky, LLP, alleges that defendants made materially false and misleading statements throughout the Class Period of March 24, 2025 through March 12, 2026 regarding the efficacy and safety prospects of the company's TACTI-004 Phase III clinical trial evaluating eftilagimod alfa (efti) in patients with advanced non-small cell lung cancer. On March 13, 2026, Immutep disclosed that the trial's Independent Data Monitoring Committee (IDMC) recommended discontinuing the study following a planned interim futility analysis, revealing that the available safety and efficacy data did not support continuation. Immutep's ADR price collapsed from $2.76 to $0.48 per share — a decline of approximately 83% — as analysts across major firms expressed shock at the outcome and downgraded the stock.

Company Profile

Immutep Limited is an Australian-based biotechnology company focused on developing LAG-3 (Lymphocyte Activation Gene-3) related immunotherapies for cancer and autoimmune diseases. The company's lead program, eftilagimod alfa (efti), is a first-in-class MHC Class II agonist that was being evaluated in combination with Merck's KEYTRUDA (pembrolizumab) and chemotherapy for the treatment of first-line advanced or metastatic non-small cell lung cancer.

Class Period

March 24, 2025 – March 12, 2026

Investors who purchased or acquired Immutep Limited (IMMP) American Depositary Receipts during the Class Period may be entitled to seek recovery under the federal securities laws.

IMMP-Infographic-Image.webp

Allegations

The complaint alleges that throughout the Class Period, Immutep and its senior executives — CEO Marc Voigt, Chief Scientific Officer Frédéric Triebel, and Chief Medical Officer Stephan Winckels — made materially false and misleading statements about the TACTI-004 Phase III trial's prospects. Defendants repeatedly characterized the trial as exhibiting "strong operational progress" and emphasized that prior studies, TACTI-002 and INSIGHT-003, demonstrated compelling efficacy and safety results that supported expectations for TACTI-004's success. These statements, according to the complaint, created an artificially positive picture of the trial's trajectory while concealing material adverse information about the risk that the study would fail to meet its primary endpoints.

Beginning with the March 24, 2025 announcement that the first patient had been dosed, the complaint alleges defendants engaged in a sustained pattern of positive statements designed to maintain investor confidence. Defendant Voigt described the dosing as "among the most significant milestones in the Company's history" and stated that the trial could be "practice changing." Defendant Triebel asserted that efti's ability to fight non-small cell lung cancer "has been demonstrated across multiple clinical trials" with "an excellent safety profile while delivering strong efficacy." In subsequent press releases through February 2026, defendants continued to tout enrollment progress, expanding site activations across 27 countries, and the potential for efti to establish a "new standard of care" — while repeatedly affirming that the planned futility analysis remained "on track."

The complaint alleges that defendants knew or recklessly disregarded that then-existing internal clinical data, analyses, and reports materially increased the risk that TACTI-004 would fail its primary efficacy and safety endpoints. Despite having access to non-public interim data from the trial, defendants allegedly continued to frame the TACTI-004 program in exclusively positive terms, omitting material safety concerns and the deteriorating likelihood of success. As late as February 6, 2026 — just weeks before the trial's discontinuation — Defendant Voigt described the enrollment pace as "excellent" and highlighted the "promise of efti," while the complaint alleges the underlying data told a fundamentally different story.

The Truth Emerges

On March 13, 2026, Immutep issued a press release disclosing that the IDMC for the TACTI-004 Phase III study had recommended discontinuing the trial following the planned interim futility analysis. Based on its review of the available safety and efficacy data, the IDMC concluded that the trial should be stopped for futility — meaning the data indicated the study was unlikely to demonstrate a meaningful treatment benefit even if carried to completion. Defendant Voigt acknowledged the company was "very disappointed and surprised with the outcome of the futility analysis, in light of efti's performance in every other clinical trial."

The disclosure directly contradicted months of positive statements from defendants about TACTI-004's progress and prospects. Multiple major analysts expressed shock at the result. Jefferies called it "a very surprising outcome, given previous efficacy and safety readouts." Baird noted that prior efti data "had shown numerically higher ORR, OS, and PFS vs. pembro + chemo alone regardless of PD(L)-1 expression levels" and stated it did "not see a clear path forward for efti." Citizens observed that "very few studies fail at the futility analysis level" and suggested the mechanism of action for efti itself would now be called into question. Maxim Group characterized the result as creating "a significant lack of clarity on the path forward for Immutep, including its efti-based pipeline programs," noting potential negative read-through across the company's entire pipeline.

Market Reaction

Immutep's ADR price suffered a catastrophic decline following the disclosure. From a closing price of $2.76 per share on March 12, 2026, IMMP fell to $0.48 per share on March 13, 2026 — a single-day decline of approximately 83%, erasing the vast majority of shareholder value. The scale of the collapse reflected the degree to which the market had relied on defendants' prior positive statements about TACTI-004's prospects. Analysts uniformly downgraded the stock: Baird slashed its price target from $7.00 to $1.00, while Maxim Group removed its prior $12.00 target entirely, underscoring the market's reassessment of the company's value following the loss of its primary pipeline asset.

Next Steps

●      Lead Plaintiff Deadline: July 6, 2026

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer

This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Immutep Limited which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Immutep Limited. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
POET Shareholders - Lead Plaintiff Deadline: June 29, 2026

POET Technologies Class Action Lawsuit – POET

 

POET Technologies Class Action Summary

Company

POET Technologies Inc. (NASDAQ: POET)

Lead Plaintiff Deadline

June 29, 2026

Class Period

April 1, 2026 – April 27, 2026 (8:57 AM ET)

Stock Drop

April 14, 2026 – POET fell $0.59 (8.08%) to $6.71; April 27, 2026 – POET fell $7.15 (47.3%) to $7.95

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against POET Technologies Inc. (NASDAQ: POET), its CEO Suresh Venkatesan, and CFO Thomas Mika on behalf of investors who purchased POET securities between April 1, 2026 and 8:57 AM ET on April 27, 2026. The complaint alleges defendants made materially false and misleading statements regarding the company's tax classification as a passive foreign investment company and its CFO's breach of a confidentiality agreement with Marvell Semiconductor Inc. When the truth emerged through a Wolfpack Research report and the subsequent cancellation of all purchase orders from Celestial AI (now owned by Marvell), POET shares suffered two sharp declines, falling 8.08% on April 14, 2026 and an additional 47.3% on April 27, 2026, causing significant losses to investors.

Company Profile

POET Technologies Inc. is a Canadian-incorporated design and development company offering photonic integrated packaging solutions based on its proprietary POET Optical Interposer platform. The company's technology allows the integration of electronic and photonic devices onto a single chip using wafer-level semiconductor manufacturing techniques, targeting high-growth areas in communications, computing, and artificial intelligence infrastructure. POET's common stock trades on the NASDAQ Capital Market under the ticker symbol POET.

Class Period

April 1, 2026 – 8:57 AM ET on April 27, 2026, inclusive.

Investors who purchased or acquired POET Technologies Inc. (POET) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the Class Period, POET Technologies and its senior executives made materially false and misleading statements on two fronts: the company's passive foreign investment company status and CFO Thomas Mika's public disclosures about the company's relationship with Marvell and Celestial AI. These misrepresentations allegedly concealed material risks to POET's valuation and business prospects from investors who relied on the company's public statements.

On March 31, 2026, POET filed its 2025 Annual Report on Form 20-F, which included certifications signed by both Venkatesan and Mika under the Sarbanes-Oxley Act. The annual report contained a risk disclosure acknowledging the company might be treated as a PFIC for the year ended December 31, 2025. According to the complaint, this disclosure materially understated the likelihood that POET would be deemed a PFIC and failed to warn investors of the practical consequences. Specifically, the complaint alleges that PFIC classification would subject U.S. shareholders to onerous tax reporting requirements and punitive tax treatment, making POET a significantly less attractive investment and threatening the company's valuation.

On April 21, 2026, after a short-seller report had already raised the PFIC issue, Defendant Mika appeared in a public interview on Stocktwits where he discussed POET's business relationship with Celestial AI, now a subsidiary of Marvell. According to the complaint, when asked whether POET was under a nondisclosure agreement with a hyperscaler, Mika stated he was in NDAs with "suppliers to hyperscalers" rather than directly with Marvell. The complaint alleged that this characterization was materially false and misleading. Mika then proceeded to discuss specific details about POET's supply relationship with Celestial AI, including that the company had an invoice from Celestial AI and intended to ship product against it, with some shipments expected the following quarter. The complaint alleges these public statements were made in breach of confidentiality obligations to Marvell, a fact Mika knew or recklessly disregarded, and that he failed to disclose the risk that such disclosures could result in termination of the business relationship.

The complaint further alleges defendants knew or recklessly disregarded that the PFIC tax classification would make POET a less attractive investment if discovered, and that Mika's public discussion of confidential business arrangements endangered the company's commercial relationship with one of its key customers. Together, these omissions and misstatements allegedly caused POET's stock price to be artificially inflated during the Class Period.

The Truth Emerges

The truth began to surface on April 14, 2026, when Wolfpack Research published a report alleging that POET was "an obvious stock promote" and that the company qualified as a passive foreign investment company under U.S. tax law. Wolfpack's analysis, which it stated was corroborated by multiple tax experts, detailed the severe compliance implications for U.S. shareholders, including the requirement to file special forms annually, pay ordinary income tax rates on both realized and unrealized gains, and face punitive compounding interest for failure to comply. One expert quoted in the report described POET's PFIC status as "obvious." The following day, April 15, 2026, POET effectively confirmed the PFIC classification by issuing a statement announcing it would make information available for U.S. shareholders to make a "QEF" election to mitigate adverse tax consequences, and Mika stated the board intended to redomicile the company in the United States to eliminate future PFIC risk.

The second and more damaging disclosure came on April 27, 2026, before the market opened at 8:58 AM ET, when POET announced the cancellation of all purchase orders from Celestial AI. The press release revealed that Marvell Semiconductor Inc. had provided written notice of the cancellation on April 23, 2026, stating that POET had made disclosures of information related to the purchase order and shipping details "in contravention of its confidentiality obligations." This directly contradicted Mika's April 21 interview statements and confirmed the complaint's allegation that his public disclosures had breached a confidentiality agreement with Marvell, with devastating commercial consequences for the company.

Market Reaction

The Wolfpack Research report triggered an immediate market response on April 14, 2026, with POET stock falling $0.59 per share, or 8.08%, to close at $6.71. The more severe impact came on April 27, 2026, when the announcement of the Celestial AI purchase order cancellation sent POET shares plunging $7.15 per share, or 47.3%, to close at $7.95. The combined disclosures wiped out substantial shareholder value as the market absorbed the dual reality that POET's PFIC status made it a less attractive investment for U.S. shareholders and that the CFO's breach of confidentiality obligations had cost the company its relationship with a key customer.

Next Steps

●       Lead Plaintiff Deadline: June 29, 2026

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in POET Technologies Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against POET Technologies Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Zoetis Inc. Class Action Lawsuit: ZTS Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Zoetis Inc. (NYSE: ZTS) concerning potential violations of the federal securities laws.

Zoetis reported Q1 2026 revenue that missed analyst consensus estimates, driven by weaker-than-expected U.S. companion animal sales and increased competitive pressure across its dermatology and pain franchises. The company simultaneously reduced its FY 2026 organic operational revenue growth guidance from the previously issued range of 3% to 5%, citing soft U.S. pet-care demand and macro-economic headwinds. Shares closed down approximately 21.50% on heavy volume. The magnitude of the market reaction reflected the gap between management's prior outlook and reported results. On the Q4 2025 earnings call in February 2026, CEO Kristin Peck had guided investors to expect 3% to 5% organic operational revenue growth for fiscal 2026. CFO Wetteny Joseph had also acknowledged that Q4 2025 international revenue included an approximate 2.5% to 3.5% one-time sales acceleration that the company did not expect to recur -- a detail that made the subsequent miss and guidance cut even more significant to investors pricing the stock on forward expectations.

If you suffered a loss on your Zoetis Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Zoetis Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Zoetis Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Hub Group, Inc. Class Action Lawsuit: HUBG Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Hub Group, Inc. (NASDAQ: HUBG) concerning potential violations of the federal securities laws.

Hub Group’s officers signed Sarbanes-Oxley certifications across multiple 10-Q and 10-K filings from 2023 through 2025 stating that each report “does not contain any untrue statement of a material fact” and “fairly presents, in all material respects, the financial condition and results of operations” of the company. The company’s 2024 10-K left the error-correction checkbox unchecked, indicating no corrections to previously issued financial statements. The Audit Committee subsequently confirmed that the financial statements underlying those certifications were materially misstated and should no longer be relied upon.

The company’s NT 10-K filing on March 3, 2026, stated that the company’s quarterly financial statements for the periods ending March 31, 2025, June 30, 2025, and September 30, 2025 “were in each case materially misstated and should no longer be relied upon.” A Form 12b-25 late-filing notice followed, and Nasdaq issued a compliance deadline.

On May 12, 2026, the issue compounded: Hub Group filed a late quarterly filing notification and a Form 8-K informing investors that the 2023 and 2024 annual financial statements similarly “should no longer be relied upon” as the Company “expects to conclude it did not maintain effective disclosure controls and procedures” for each of those years.

If you suffered a loss on your Hub Group, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Hub Group, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Hub Group, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join ZoomInfo Technologies Inc. Class Action Lawsuit: GTM Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into ZoomInfo Technologies Inc. (NASDAQ: GTM) concerning potential violations of the federal securities laws.

During the Q4 2025 earnings call, CFO Graham O'Brien stated: "All above the guidance ranges we provided at the beginning of the year and, again, above our updated guidance as we beat and raise throughout the year." On that same call, the company issued lofty FY 2026 guidance, highlighting projected revenue of $1.247 billion - $1.267 billion and projected operating income of $456 million to $466 million. Separately, during the first quarter earnings call on May 11, 2026, CFO Graham O'Brien characterized the Q1 as “a solid quarter,” but one that highlighted the “improving trends” from 2025 were now “starting to moderate.” Zoom slashed its revenue guidance nearly 5%, now expecting revenue of only $1.185 billion to $1.205 billion, and similarly cut its operating income projection more than 4% to $437 million to $447 million.

If you suffered a loss on your ZoomInfo Technologies Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in ZoomInfo Technologies Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against ZoomInfo Technologies Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Azenta, Inc. Class Action Lawsuit: AZTA Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Azenta, Inc. (NASDAQ: AZTA) concerning potential violations of the federal securities laws.

On February 4, 2026, CEO John Marotta told investors Azenta was "entering the year well positioned for continued success" and reaffirmed FY 2026 guidance of 3%-5% organic revenue growth with approximately 300 basis points of adjusted EBITDA margin expansion. On May 5, 2026, the Company reported Q2 FY 2026 results that included a $149 million goodwill impairment charge in its Multiomics segment. The resulting net loss of $160.8 million stood in stark contrast to the growth trajectory management had presented ninety days prior. Alongside the impairment, Azenta reduced its full-year FY 2026 guidance -- trimming the revenue growth and margin expansion targets it had publicly reaffirmed in February. The gap between the Company's stated outlook and its reported results is now the subject of an investigation into potential securities law violations.

If you suffered a loss on your Azenta, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Azenta, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Azenta, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Peabody Energy Corporation Class Action Lawsuit: BTU Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Peabody Energy Corporation (NYSE: BTU) concerning potential violations of the federal securities laws.

During the Q4 2025 earnings call on February 5, 2026, CFO Mark A. Spurbeck told investors that full-year 2025 results "met or exceeded original guidance for seven of eight volume and cost metrics." CEO James C. Grech described the company as sitting "at the intersection of multiple policy and market trends…moving in a highly favorable direction" -- a statement made shortly before the Q1 2026 earnings release disclosed a net loss of $32.4 million, a decline in adjusted EBITDA, and surging diesel costs that had not been adequately disclosed to investors. The gap between the guidance narrative and actual results was stark. Management projected costs "consistent with 2025 levels" while diesel expenses climbed materially. The Centurion mine -- described by the CEO as "well ahead of its original schedule" in February -- was disclosed as delayed, removing expected production volume from the 2026 outlook.

If you suffered a loss on your Peabody Energy Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Peabody Energy Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Peabody Energy Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Upwork Inc. Class Action Lawsuit: UPWK Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Upwork Inc. (NASDAQ: UPWK) concerning potential violations of the federal securities laws.

During the Q4 2025 earnings call on February 9, 2026, CEO Hayden Brown stated that revenue growth was "2.4%" and adjusted EBITDA margin was "29%" for the full year, and guided for "6%-8% revenue growth" in 2026. Within weeks, the Company cut its Q2 2026 guidance and revised revenue expectations downward. On the same call, management stated the Company “embedded more AI functionality in the Marketplace” and estimated these “improvements contributed $100 million in incremental GSV in 2025” and “GSV from AI-related work surpassed $300 million on an annualized basis in Q4, up more than 50% from the prior year.” When Q1 2026 results revealed the gap between prior statements and actual performance, UPWK shares fell 19%.

If you suffered a loss on your Upwork Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Upwork Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Upwork Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
GPK Shareholders - Lead Plaintiff Deadline: July 06, 2026

Graphic Packaging Holding Company Class Action Lawsuit – GPK

Graphic Packaging Class Action Summary

Company

Graphic Packaging Holding Company (NYSE: GPK)

Lead Plaintiff Deadline

July 6, 2026

Class Period

February 4, 2025 – February 2, 2026

Stock Drop

May 1, 2025 – GPK fell $3.94 (15.57%) to $21.37; December 9, 2025 – GPK fell $1.35 (8.66%) to $14.23; February 3, 2026 – GPK fell $2.36 (15.97%) to $12.42

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Graphic Packaging Holding Company (NYSE: GPK), its former President and CEO Michael P. Doss, and its former Executive Vice President and CFO Stephen R. Scherger by plaintiff Michael Thurber, represented by Pomerantz LLP. The lawsuit covers a class period from February 4, 2025 through February 2, 2026, during which the complaint alleges defendants made materially false and misleading statements regarding the strength and sustainability of Graphic Packaging's business model, its ability to manage inventory effectively, and the reliability of its full-year 2025 financial guidance. According to the complaint, the truth emerged through a series of corrective disclosures beginning in May 2025, when the company slashed its financial outlook, followed by further guidance cuts in December 2025 and disappointing fourth quarter results in February 2026. Investors suffered significant losses as GPK's stock price declined sharply after each disclosure, falling from the mid-$20s to $12.42 per share over the course of the class period.

Company Profile

Graphic Packaging Holding Company, together with its subsidiaries, designs, produces, and sells consumer packaging products. Its customers include businesses in the food, foodservice, beverage, household, and other consumer product industries across the Americas, Europe, and the Asia Pacific region, with products sold through sales offices and broker arrangements with third parties.

Class Period

February 4, 2025 – February 2, 2026

Investors who purchased or acquired Graphic Packaging Holding Company (GPK) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the class period, defendants repeatedly touted the purported strength and stability of Graphic Packaging's business model and its ability to deliver on cost reduction, inventory management, free cash flow, and profitability targets — even as the company was experiencing significant inventory management problems, reduced demand and volumes, and rising costs that undermined those representations. In February 2025, defendant Doss characterized the company's results as "consistent," "profitable," and "strong and steady," and issued full-year 2025 guidance projecting net sales of $8.7 billion to $8.9 billion, adjusted EBITDA of $1.68 billion to $1.78 billion, and adjusted EPS of $2.53 to $2.78. The complaint alleges these projections were unreliable and unrealistic given the operational challenges defendants knew the company faced.

When analysts specifically questioned whether Graphic Packaging's elevated inventory levels were a concern, defendant Doss represented that the buildup was intentional — necessary to protect customers during the startup of a new paperboard mill in Waco, Texas — and assured investors that the excess inventory would "wash through pretty quickly." According to the complaint, these assurances were materially misleading because the company was already grappling with inventory management issues far more severe than defendants acknowledged. Defendant Scherger similarly emphasized "strong and steady margins" and characterized the business model as resilient even at the bottom of the guidance range.

After the first corrective disclosure in May 2025 forced a dramatic downward revision of the company's outlook, the complaint alleges defendants continued to mislead investors by downplaying the severity of the problems. Defendant Doss characterized volume declines as "small" and assured the market that challenges were "not long-term in nature." Over the following months, defendants repeatedly stressed their ability to actively manage inventory and match supply to demand. Defendant Scherger stated the company was "aggressively matching supply and demand" and touted having removed "over 50,000 tons of inventory" in the first half. The complaint alleges these statements concealed the true scope of the company's deteriorating operations and the unreliability of its revised financial guidance, which would be cut again twice before the class period ended.

The complaint further alleges that the Individual Defendants had both the motive and opportunity to commit fraud. During the class period, defendant Doss sold nearly 1.6 million shares of Graphic Packaging common stock, enriching himself by over $7 million, while defendant Scherger sold 65,529 shares, enriching himself by nearly $1.8 million. As the company's most senior executives who personally signed Sarbanes-Oxley certifications attesting to the accuracy of Graphic Packaging's financial filings, the Individual Defendants had direct access to internal information about the company's inventory levels, demand trends, and cost pressures, and the complaint alleges they knew or recklessly disregarded that their public statements were materially false and misleading.

The Truth Emerges

The truth began to surface on May 1, 2025, when Graphic Packaging reported first quarter 2025 results that fell well short of market expectations. The company reported non-GAAP EPS of $0.51, missing consensus estimates by $0.07, and revenue of $2.12 billion, a 6.2% year-over-year decline that also missed estimates by $10 million. More significantly, Graphic Packaging slashed its full-year 2025 guidance across every major metric: net sales were revised down to $8.2 billion to $8.5 billion from $8.7 billion to $8.9 billion, adjusted EBITDA was cut to $1.4 billion to $1.6 billion from $1.68 billion to $1.78 billion, and adjusted EPS was reduced to $1.75 to $2.25 from $2.53 to $2.78. The company attributed the revisions to an expected 2% volume decline, $80 million of input cost inflation, and "higher macroeconomic and consumer spending uncertainty" — the very headwinds the complaint alleges defendants had previously downplayed.

The truth continued to emerge on December 8, 2025, when Graphic Packaging disclosed that it was accelerating inventory reduction plans originally scheduled for 2026 into the fourth quarter, with production curtailments expected to cost an additional $15 million on top of $15 million in curtailments already announced. The company again cut its full-year 2025 guidance, reducing expected adjusted EBITDA to $1.38 billion to $1.43 billion and adjusted EPS to $1.75 to $1.95. In a separate press release issued the same day, Graphic Packaging announced that defendant Doss had "mutually agreed" with the board of directors to step down as President, CEO, and director, effective December 31, 2025 — a departure multiple analysts characterized as "unexpected."

The final corrective disclosure came on February 3, 2026, when Graphic Packaging reported fourth quarter non-GAAP EPS of $0.29, missing consensus estimates by $0.06, and revealed that fourth quarter adjusted EBITDA had declined 19% year-over-year due to lower volumes, increased costs, and inventory reduction decisions. The company projected a meaningful decline in 2026 adjusted EBITDA as well, citing a $130 million negative impact from inventory reduction actions, an approximately $100 million incentive compensation accrual, and weather-related production impacts. New CEO Robbert Rietbroek announced a "comprehensive review" of Graphic Packaging's organization structure, operations, and footprint — a statement the complaint alleges confirmed the weakness and unsustainability of the business model defendants had spent the class period championing.

Market Reaction

The market reacted sharply to each corrective disclosure. On May 1, 2025, GPK fell $3.94 per share, or 15.57%, to close at $21.37 — the largest single-day decline since October 2018, according to Bloomberg. Trading volume surged to 8.39 million shares, more than three times the average daily volume of 2.73 million, and the stock touched a new 52-week low of $21.16 during intraday trading.

On December 9, 2025, following the accelerated inventory reduction announcement and the unexpected CEO departure, GPK fell $1.35, or 8.66%, to close at $14.23. Bloomberg reported that the stock opened down more than 8% with trading volume at more than seventeen times the 20-day average for that time of day.

The most severe reaction came on February 3, 2026, when GPK fell $2.36, or 15.97%, to close at $12.42 following the disappointing fourth quarter results and weak 2026 outlook. Analyst reactions were uniformly negative: Jefferies described the results as "disappointing," stating the company "will likely be in the penalty box for some time." Raymond James wrote that the quarterly result was "completely overshadowed by a disappointing 2026 guide." RBC Capital Markets noted the 2026 guidance was "Significantly Below-Street" expectations, and Wells Fargo cited "repeated EBITDA guidance cuts and mounting competitive pressure" in downgrading the stock.

Next Steps

●      Lead Plaintiff Deadline: July 6, 2026

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Graphic Packaging Holding Company which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Graphic Packaging Holding Company. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
FSK Shareholders - Lead Plaintiff Deadline: July 06, 2026

FS KKR Capital Corp. Class Action Lawsuit – FSK

FS KKR Capital Class Action Summary

Company

FS KKR Capital Corp. (NYSE: FSK)

Lead Plaintiff Deadline

July 6, 2026

Class Period

May 8, 2024 – February 25, 2026

Stock Drop

August 7, 2025 – FSK fell $1.66 (8.20%) to $18.58; February 26, 2026 – FSK fell $2.03 (15.24%) to $11.29

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against FS KKR Capital Corp. (NYSE: FSK), its Chief Executive Officer Michael C. Forman, and its Chief Financial Officer Steven Lilly in the United States District Court for the Eastern District of Pennsylvania. The complaint, filed by plaintiff Calvin Stuart through Glancy Prongay & Wolke LLP, alleges that defendants made materially false and misleading statements between May 8, 2024 and February 25, 2026, overstating the effectiveness of the Company's portfolio restructuring efforts, the accuracy of its portfolio valuations, and the durability of its shareholder distribution strategy. As the truth emerged through two corrective disclosures revealing accelerating portfolio deterioration, rising non-accrual rates, and a dividend cut, FSK shares suffered cumulative declines exceeding 23%, causing significant losses to investors who purchased shares during the Class Period.

Company Profile

FS KKR Capital Corp. is a Business Development Company ("BDC") that specializes in making private loans to companies. The Company's principal source of revenue is interest income earned on its debt investments, as well as fees and dividends from its portfolio companies. FS KKR Capital's common stock trades on the New York Stock Exchange under the ticker symbol FSK, and its principal executive offices are located in Philadelphia, Pennsylvania.

Class Period

May 8, 2024 – February 25, 2026

Investors who purchased or acquired FS KKR Capital Corp. (FSK) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the Class Period, FS KKR Capital and its senior executives painted a picture of steady portfolio improvement and disciplined risk management that did not reflect the true condition of the Company's investment portfolio. Beginning with first quarter 2024 results announced on May 8, 2024, CEO Michael C. Forman repeatedly assured investors that the Company had made "significant progress restructuring certain non-accruing investments" and that the "long-term earnings power of FSK continues to be healthy." Over five consecutive quarters, management touted declining non-accrual rates, portfolio stability, and the Company's ability to "continue rewarding shareholders with attractive distributions."

According to the complaint, these statements were materially false and misleading because defendants overstated the effectiveness of the Company's portfolio restructuring efforts for its non-accrual companies. Each quarter from Q1 2024 through Q1 2025, management highlighted declining non-accrual rates — from 4.2% at fair value in Q1 2024 down to 1.7% in Q3 2024 — as evidence of a successful workout strategy. CEO Forman's quarterly press releases emphasized themes of "portfolio stability," "strong performance," and "disciplined capital deployment," while the Company's SEC filings repeatedly certified that its disclosure controls, internal controls over financial reporting, and board-supervised valuation processes were all operating effectively.

The complaint further alleges that defendants overstated the valuation of the Company's portfolio investments and the effectiveness of its valuation process. As a BDC, FS KKR Capital is required to carry its investments at fair value, and its net asset value per share is a critical metric investors use to assess the Company's financial health. The complaint contends that the reported NAV figures — which ranged from $24.32 in Q1 2024 to $23.37 in Q1 2025 — did not accurately reflect the deteriorating condition of key portfolio holdings, including investments in Production Resource Group, 48forty, Kellermeyer Bergensons Services, Worldwise, Medallia, and Cubic Corp. Moreover, plaintiffs allege that defendants overstated the durability of the Company's quarterly distribution strategy, which was ultimately cut from $0.70 to $0.48 per share when the depth of portfolio problems could no longer be concealed.

The Truth Emerges

The truth began to partially emerge on August 6, 2025, when FS KKR Capital reported second quarter 2025 earnings after the market closed. The results revealed that net asset value had plummeted to $21.93 per share — a decline of $1.44, or 6.2%, from the prior quarter — while the total fair value of investments fell $474 million to $13.648 billion. The Company reported a loss per share of negative $0.75, a swing of $1.18 or 274.4% from the prior quarter's positive earnings, and total net realized and unrealized losses of negative $1.36 per share, a deterioration of 466.7%. Non-accrual investments surged to 3.0% and 5.3% of the portfolio at fair value and amortized cost, respectively, up from 2.1% and 3.5% just one quarter earlier. In the accompanying earnings call, Chief Investment Officer Daniel Pietrzak identified four troubled portfolio companies — Production Resource Group, 48forty, Kellermeyer Bergensons Services, and Worldwise — as the primary drivers of the decline, acknowledging that three were "larger investments" in the portfolio. Despite the severity of the disclosure, management maintained that these were merely "company specific issues" that had been "discussed on prior earnings calls."

The full scope of the Company's portfolio deterioration was revealed on February 25, 2026, when FS KKR Capital announced fourth quarter and full year 2025 earnings. Net asset value had declined further to $20.89 per share — down $1.10, or 5%, from the prior quarter — and the total fair value of investments fell another $406 million to $13.009 billion. The Company reported a loss per share of negative $0.41 and total net realized and unrealized losses of negative $0.89 per share. Non-accrual investments climbed again to 3.4% and 5.5% of the portfolio at fair value and amortized cost. Critically, Pietrzak was forced to acknowledge that the Company's "recent underperformance reflects challenges in certain legacy investments" as well as "challenges in certain current adviser originated investments such as Medallia, Cubic Corp, KBS and 48forty" — revealing that the problems extended well beyond the four companies identified in the August disclosure. The four largest problem investments accounted for only "50% of net realized and unrealized losses," meaning that half of the Company's losses came from additional, previously undisclosed portfolio weaknesses. Pietrzak also conceded that the Company's non-accrual rate was "above the long-term BDC industry average cost basis, nonaccrual rate of approximately 3.8%." The Company simultaneously slashed its quarterly dividend to $0.48 per share from $0.70, directly contradicting months of assurances about distribution stability.

Market Reaction

Following the partial disclosure on August 6, 2025, FSK shares fell $1.66, or 8.20%, to close at $18.58 per share on August 7, 2025, on unusually heavy trading volume. The market's reaction reflected investors' reassessment of the Company's portfolio health, though management's characterization of the problems as isolated to four specific companies temporarily limited the damage.

The far more severe correction came after the February 25, 2026 disclosure. On February 26, 2026, FSK shares plunged $2.03, or 15.24%, to close at $11.29 per share on unusually heavy trading volume. The magnitude of the decline reflected investors' realization that portfolio deterioration was far more widespread than previously disclosed, that the Company's non-accrual rate had breached the industry average, and that the dividend cut undermined the distribution stability narrative that had been central to management's investor communications throughout the Class Period.

Next Steps

●      Lead Plaintiff Deadline: July 6, 2026

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in FS KKR Capital Corp which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against FS KKR Capital Corp. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join GeneDx Holdings Corp. Class Action Lawsuit: WGS Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into GeneDx Holdings Corp. (NASDAQ: WGS) concerning potential violations of the federal securities laws.

On its Q4 2025 earnings call on February 23, 2026, CFO Kevin Feeley told investors the company expected "adjusted net income positive for the full year and each individual quarter" of 2026. GeneDx then reported Q1 2026 adjusted EPS of -$0.28 -- versus consensus expectations of -$0.01 -- representing an adjusted net loss of $8.2 million in the same quarter management had projected would be profitable. The stock fell approximately 41% to 49% after Q1 2026 results, as adjusted EPS of $0.28 significantly missed consensus -$0.01 consensus, widening the gap between the numbers investors were given and the results that followed.

If you suffered a loss on your GeneDx Holdings Corp. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in GeneDx Holdings Corp. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against GeneDx Holdings Corp. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Embecta Corp. Class Action Lawsuit: EMBC Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Embecta Corp. (NASDAQ: EMBC) concerning potential violations of the federal securities laws.

On November 25, 2025, CFO Jacob P. Elguicze provided initial FY2026 revenue guidance of $1.071 billion to $1.093 billion, stating the company anticipated revenues would be "flat to down 2%" compared to FY2025. On February 5, 2026, during the Q1 FY2026 earnings call, Elguicze reaffirmed those ranges while noting the company expected results "closer to the lower end" due to "incremental US pricing headwinds." The full-year guidance was not cut at that time. When Q2 FY2026 were reported, Embeca posted weaker-than-expected revenue and subsequently reduced its full-year outlook. EMBC shares dropped more than 25% in a single session. The update marked a reversal from prior guidance reaffirmations made in earlier earnings communications within the same fiscal year.

If you suffered a loss on your Embecta Corp. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Embecta Corp. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Embecta Corp. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Roblox Corporation Class Action Lawsuit: RBLX Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Roblox Corporation (NYSE: RBLX) concerning potential violations of the federal securities laws.

On the Q4 2025 earnings call (February 5, 2026), CEO David Baszucki stated that the company's facial-age-estimation rollout had "achieved 45% penetration of global DAUs" and that the safety controls would cause only a "temporary" effect on user activity. CFO Naveen Chopra guided for FY 2026 bookings growth of 22% to 26%. Subsequently on the Q1 2026 earnings call, CFO Chopra lowered guidance reducing actual expected growth to 8-12%. On the Q3 2025 earnings call (October 30, 2025), Baszucki had similarly characterized the rollout's impact as limited, stating management believed it would "add long-term value creation for shareholders, even if there are any short-term headwinds." The gap between these characterizations and the subsequently disclosed financial impact drove the stock decline that caused investor losses.

If you suffered a loss on your Roblox Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Roblox Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Roblox Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Gemini Space Station, Inc. Class Action Lawsuit – GEMI

Introduction to Gemini Space Station, Inc. (GEMI) Securities Class Action Lawsuit

A securities fraud class action has been filed against Gemini Space Station, Inc. (NASDAQ: GEMI) alleging violations of Sections 11 and 15 of the Securities Act of 1933, and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in connection with its September 12, 2025 initial public offering and subsequent trading through February 17, 2026, on the NASDAQ Global Select Market under ticker symbol GEMI. The company sold 15,178,572 shares of Class A common stock at $28.00 per share in the IPO. Investors allege that Gemini misrepresented the viability of its core cryptocurrency platform business and its commitment to international expansion from the IPO through the class period. Within five months of going public, the company announced a dramatic corporate pivot, slashed its workforce by 25%, and abandoned the very international markets it had touted as central to growth. Shares fell to $6.585, a decline of approximately 76.5% from the offering price.

Gemini Space Station, Inc. (GEMI) Securities Lawsuit Case Details

Case Name: Marc A. Methvin v. Gemini Space Station, Inc., et al.

Case No.: 1:26-cv-02261

Jurisdiction: U.S. District Court, Southern District of New York

Filed on: March 18, 2026

Gemini Space Station, Inc. (GEMI) Company Profile

Gemini Space Station, Inc. is a Nevada corporation that operates a cryptocurrency platform and is publicly traded on the NASDAQ. Historically, Gemini has primarily generated revenue through transaction, deposit, and other fees charged to users of its crypto platform. The complaint describes Gemini’s core exchange product and related offerings, including a derivatives exchange, staking services, an OTC trading desk, institutional-grade custody, a NYDFS-regulated stablecoin, a U.S. credit card, and a Web3 studio for NFTs.

Gemini Space Station, Inc. (GEMI) Securities Lawsuit Class Period

Class Period: September 12, 2025 through February 17, 2026, inclusive.

Investors who purchased Gemini Class A common stock pursuant and/or traceable to the Offering Documents issued in connection with the company's initial public offering conducted on or about September 12, 2025, including the final prospectus on Form 424B4, and/or Gemini securities during the Class Period might be eligible to join the Gemini Space Station, Inc. (GEMI) class action lawsuit.

Allegations in the Gemini Space Station, Inc. (GEMI) Securities Class Action Lawsuit

On September 12, 2025, Gemini completed its IPO on the NASDAQ Global Select Market, selling shares to the public at $28.00 each. The Registration Statement on Form S-1 and prospectus on Form 424B4 filed September 15, 2025 painted an ambitious vision. Gemini told investors it envisioned a future where crypto would redesign the global financial system and provide greater choice and opportunity for all. The company stated it was predominantly focused on expanding its exchange platform through increased monthly transacting users, increased average daily trading volume, and increasing the number of assets available on its platform. Geographic expansion into new markets and jurisdictions would amplify its global reach, the company promised, noting that crypto is inherently global and operates 24/7, underpinning its focus on investments in both the European and Asia-Pacific regions, including launches in the United Kingdom, the European Union and Australia.

During the months following the IPO, executives reinforced these commitments. On November 10, 2025, President Cameron Winklevoss told investors that Gemini had broadened its global footprint by launching in Australia and securing its MiCA license in Europe, enabling the company to offer staking, derivatives and tokenized stocks to customers across the European Union under a regulated framework. He stated this performance reinforced the strength of the model and the foundation that would continue to power Gemini's long-term growth. Chief Operating Officer Marshall Beard announced the company had received its MiCA license from the Malta Financial Services Authority, enabling it to offer crypto services across all 30 European countries and jurisdictions. Chief Financial Officer Dan Chen told investors the company continued to expect monthly transacting users to grow at a 20% to 25% compound rate over the medium term, supported by new retail customers and expanding engagement from existing customers.

Investors allege that throughout this period, Gemini had overstated the viability of its core business as a crypto platform and its commitment to expanding its international operations, failed to disclose a plan to pivot to a prediction market strategy, and to scale back certain international operations. The company's post-IPO financial and business prospects were overstated, investors claim, the Offering Documents contained untrue statements of material fact, and omitted material information pertinent to investors, actionable under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, and all of this raised a non-speculative risk that Gemini was poised for an expensive and disruptive restructuring.

The Truth Emerges

The truth began to emerge on February 5, 2026, when Gemini, filing a Form 8-K with the U.S. Securities and Exchange Commission announced a corporate pivot to "Gemini 2.0." Co-founders Tyler and Cameron Winklevoss revealed three dramatic changes. The prediction market would be more front and center in the company's experience. Gemini would reduce its workforce by 25%. And the company would exit the United Kingdom, European Union, and Australian markets-markets that executives had recently highlighted; the Offering Documents also described international expansion as creating "a robust foundation for sustained growth". Management stated that in order to have the necessary bandwidth to succeed in the company's new emphasis on prediction markets, Gemini would narrow its focus by exiting the UK, EU, and Australian markets.

On February 17, 2026, via a Form 8-K, Gemini disclosed the departure of three top executives: Marshall Beard, its former Chief Operating Officer; Dan Chen, its former Chief Financial Officer; and Tyler Meade, its former Chief Legal Officer. The company also released preliminary unaudited estimates showing net revenue of $165 million to $175 million and operating expenses of $520 million to $530 million, an increase of approximately 40% from the previous fiscal year. The estimated increase in operating expenses was primarily due to higher personnel-related costs, including stock-based compensation, and investments in technology, general and administrative expenses, and marketing.

Market Reaction

On February 5, 2026, when Gemini announced its corporate pivot and international market exits, shares (NASDAQ: GEMI) fell $0.64 per share, or 8.72%, to close at $6.70 per share, on the NASDAQ Global Select Market-76.1% below the $28.00 offering price.

On February 17, 2026, following the executive departures and expense disclosure, the stock fell another $0.975 per share, or 12.9%, to close at $6.585 per share, and traded below $7 per share intraday.

From the September 12, 2025 IPO through February 17, 2026, Gemini shares suffered a precipitous decline of approximately $21.415 per share, or 76.5%, leaving the stock trading far below the price investors paid just five months earlier.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Gemini Space Station, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Gemini Space Station, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Gildan Activewear Inc. Class Action Lawsuit: GIL Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Gildan Activewear Inc. (NYSE: GIL) concerning potential violations of the federal securities laws.

The timeline leading to the December 11, 2023 announcement included no indication of governance disruption. On May 3, 2023, CEO Glenn Chamandy told investors on the Q1 earnings call: "We are playing right where we want to be... we are gaining share in every category... we are outperforming the market." On December 11, 2023, the Gildan board announced it had terminated Chamandy and appointed Vince Tyra to be president and CEO. GIL shares immediately fell 10% in a single session. After a lengthy and high-profile proxy battle in which Gildan spent over $70 million on legal and financial advisors and other costs, shareholders voted to reinstate Chamandy to the board at the annual meeting held on May 28, 2024 and to elect a new board of directors. Vince Tyra (replacement CEO) and the remainder of the old board departed.

If you suffered a loss on your Gildan Activewear Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Gildan Activewear Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Gildan Activewear Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Option Care Health, Inc. Class Action Lawsuit: OPCH Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Option Care Health, Inc. (NASDAQ: OPCH) concerning potential violations of the federal securities laws.

The Q1 2026 earnings report revealed a revenue shortfall against analyst expectations. The Company simultaneously reduced its FY 2026 revenue guidance by up to 3.75% -- a cut of as much as $225 million from the top end of its prior range. The revised outlook of $5.675 billion-$5.775 billion represented a sharp departure from the $5.8 billion-$6.0 billion range that CEO John Rademacher and CFO Meenal Sethna had reaffirmed just 65 days earlier on the Q4 2025 earnings call on February 24, 2026. The Company cited increased headwinds from the Stelara biosimilar conversion as a contributing factor. On February 24, 2026, CFO Sethna had quantified this headwind at $25 million-$35 million for FY 2026. By April 30, the headwind had increased to $55 million, as “the number of Stelara patients converting to some other therapy” was below expectations, leading to a drop in census and revenue expectations. The projected “400 basis point revenue growth headwind” had quickly jumped to “600 basis points” of CID portfolio headwinds.

If you suffered a loss on your Option Care Health, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Option Care Health, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Option Care Health, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Merchants Bancorp Class Action Lawsuit: MBIN Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Merchants Bancorp (NASDAQ: MBIN) concerning potential violations of the federal securities laws.

The Q1 2026 earnings release showed what appeared to be a headline beat. Beneath that number, brokered deposits -- a key funding source for the bank -- had declined approximately 50% compared to Q1 2025. At the same time, the Company's cost of funds increased materially. The market's reaction was immediate: MBIN shares fell 9.3% as investors recalculated the sustainability of the Company's earnings trajectory in light of the deposit contraction and funding-cost pressure. Prior to the Q1 2026 release, the Company had emphasized "strong deposit growth" in communications with investors. The earnings report did not reconcile that characterization with the scale of the brokered-deposit decline. Analysts and investors who had relied on prior deposit-growth messaging absorbed the new data and sold.

If you suffered a loss on your Merchants Bancorp securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Merchants Bancorp which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Merchants Bancorp. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Qiagen N.V. Class Action Lawsuit: QGEN Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Qiagen N.V. (NYSE: QGEN) concerning potential violations of the federal securities laws.

During the previous earnings call on February 5, 2026, CEO Thierry Bernard was confident: “You will see QuantiFERON picking up in Q2 … accelerating to achieve … between 6% and 7% growth” in 2026. He noted Qiagen’s projections remained “perfectly aligned with the target that we gave during our Capital Market Day in June 2024.” On April 28, 2026, Qiagen walked back on these claims and CFO Roland Sackers revealed the disappointing guidance: sales were now projected to “continue at a largely unchanged level from the second quarter of 2025,” and investors would have to wait for QuantiFERON to “return to a more normalized growth rate in 2027.”

If you suffered a loss on your Qiagen N.V. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Qiagen N.V. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Qiagen N.V. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
CIGL Shareholders - Lead Plaintiff Deadline: May 20, 2026

Concorde International Group, Ltd. Class Action Lawsuit – CIGL

Introduction to Concorde International Group, Ltd. (CIGL) Securities Class Action Lawsuit

A securities fraud class action under the Securities Exchange Act of 1934 and Rule 10b-5 has been filed against Concorde International Group, Ltd. (NASDAQ: CIGL), a British Virgin Islands company whose Class A Ordinary Shares trade on the NASDAQ Capital Market under the ticker CIGL and certain officers, directors, auditors, and underwriters for the period between April 21, 2025, and July 14, 2025. Investors allege that defendants misrepresented the legitimacy of the company’s securities trading activity and concealed that Concorde International Group, Ltd. was the subject of a fraudulent stock promotion scheme involving social media-based misinformation targeting retail investors and impersonated financial professionals. Behind the scenes, insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares through artificial trading activity during a price inflation campaign. In July 2025, Concorde International Group, Ltd.’s stock fell approximately 80% in a single day. The complaint alleges the decline occurred after a dramatic run-up that plaintiff contends was tied to a fraudulent stock-promotion scheme later discussed in media reports and broader regulatory actions concerning similar foreign micro-cap trading patterns.

Concorde International Group, Ltd. (CIGL) Securities Lawsuit Case Details

Case Name: Parthasarathy Krishnamoorthy v. Concorde International Group, Ltd., et al.

Case No.: 1:26-cv-02283

Jurisdiction: U.S. District Court, Southern District of New York

Filed on: March 19, 2026

Concorde International Group, Ltd. (CIGL) Company Profile

Concorde International Group, Ltd. claims to be an integrated security services provider headquartered in Singapore , incorporated in the British Virgin Islands and operating as a foreign private issuer that files Form 20-F annual reports that combines physical manpower and innovative technology to deliver security solutions, with Class A Ordinary Shares listed on Nasdaq under ticker CIGL, with approximately 97-99% of revenues purportedly derived from its i-Guarding Services consisting of electronic security systems and mobile patrols.

Concorde International Group, Ltd. (CIGL) Securities Lawsuit Class Period

April 21, 2025 – July 14, 2025, inclusive.

All persons and entities that purchased or otherwise acquired Concorde International Group, Ltd. securities including Class A Ordinary Shares during the Class Period and who were damaged thereby may be eligible to join the Concorde International Group, Ltd. (CIGL) class action lawsuit.

Allegations in the Concorde International Group, Ltd. (CIGL) Securities Class Action Lawsuit

The complaint targets Concorde International Group, Ltd., its Chief Executive Officer and Chairman Swee Kheng Chua, Chief Financial Officer Sze Yin Ong, Directors Terence Wing Khai Yap and Mark Allen Brisson, auditor Kreit and Chiu CPA, LLP, underwriter R.F. Lafferty & Co., Inc., and agent Cogency Global Inc. for allegedly orchestrating or enabling a pump-and-dump scheme and making materially false and misleading statements and omissions in violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5.

On April 21, 2025, Concorde International Group, Ltd. completed its initial public offering at $4.00 per share on the NASDAQ Capital Market, with the IPO prospectus touting the company as an award-winning integrated security services provider with 113% revenue growth from 2022 to 2023 and strong recurring contract revenue. The prospectus highlighted that i-Guarding Services accounted for over 98% of consolidated revenues and emphasized the company’s technological innovation and market leadership in Singapore , while omitting adverse material facts about artificial trading activity and stock promotion.

During the following weeks, CEO Swee Kheng Chua issued statements reinforcing this optimistic narrative. On May 16, 2025, he described 2024 as a transformative year culminating in the successful IPO that raised $5.75 million in gross proceeds, claiming the milestone validated the business model and provided capital to accelerate growth without disclosing the alleged stock promotion driving trading activity. He projected strong year-over-year growth driven by high-margin recurring revenue from i-Guarding services and announced plans to expand internationally into Malaysia, Australia, and North America over the next 24 months , statements investors allege were misleading in light of undisclosed artificial trading activity.

On June 17, 2025, Chua announced that the company had secured more than $9 million in new contracts through May 2025, already surpassing the total value of contracts signed in all of 2024, stating this validated market confidence in Concorde International Group, Ltd.’s solutions , which investors allege ignored the effects of a coordinated stock promotion campaign on price and volume.

Investors allege that these positive statements omitted the material fact that Concorde International Group, Ltd. was the subject of a fraudulent stock promotion scheme and failed to disclose artificial trading activity driving the stock price. The complaint alleges that social media ads were being used to mass target retail investors in different countries, pushing them to join Telegram and WhatsApp groups where impersonators posing as financial professionals instructed them to buy Concorde International Group, Ltd. stock and hold for five days for guaranteed returns. Meanwhile, insiders and affiliates allegedly used offshore or nominee accounts to facilitate the coordinated dumping of shares as the stock price artificially inflated from $4.00 to over $31.00. The auditor Kreit and Chiu allegedly issued fraudulent audit opinions that enabled the scheme, while underwriter R.F. Lafferty failed to conduct adequate due diligence before bringing the company public.

The Truth Emerges

The alleged fraud began to surface on June 16, 2025, when the Wall Street Journal published an article titled “Obscure Chinese Stock Scams Dupe American Investors by the Thousands” describing similar social-media-driven stock-promotion schemes involving low-float Nasdaq-listed companies.

On July 10, 2025, Concorde International Group, Ltd.’s stock price abruptly crashed approximately 80% to $5.66 on the NASDAQ market. The complaint alleges that investigations and public reports later detailed how CIGL stock had been used in an alleged pump-and-dump promotion scheme. That same day, TradeInformer published an exclusive article titled “Pump and dump scammers target Concorde International Group at market open Thursday” detailing the parallels between the Concorde International Group, Ltd. fraud and a similar scheme involving Ostin Technology. The article revealed that brokers such as DEGIRO had restricted access to Concorde International Group, Ltd. stock after recognizing it as a fraud, and explained how perpetrators used social media ads to push investors into Telegram and WhatsApp groups where they were instructed to buy stock and hold for five days.

On July 17, 2025, The Bear Cave published “Problems in Chinatown” identifying Concorde International Group, Ltd. as part of a broader pattern of fraudulent Chinese micro-cap IPOs. Later in 2025, Nasdaq, the SEC, DOJ, and the Public Company Accounting Oversight Board (“PCAOB”) announced actions addressing similar foreign micro-cap manipulation concerns and related gatekeeper issues, which the complaint cites as broader context.

On September 3, 2025, Nasdaq issued a press release proposing changes to its listing standards in response to emerging patterns associated with potential pump-and-dump schemes, including a $15 million minimum market value of public float and a $25 million minimum public offering proceeds requirement for companies principally operating in China.

On September 5, 2025, the SEC announced formation of a Cross-Border Task Force to Combat Fraud, specifically identifying auditors and underwriters as gatekeepers who enable pump-and-dump schemes perpetrated by foreign-based companies including those from China.

On September 12, 2025, the DOJ indicted Ostin Technology’s Co-CEO and a financial advisor for orchestrating a social media-based pump-and-dump scheme with virtually identical characteristics to Concorde International Group, Ltd.’s, alleging defendants inflated market capitalization from $22 million to over $1 billion while fraudulently obtaining more than $110 million in proceeds.

On December 4, 2025, the PCAOB sanctioned Ostin Technology’s auditor TPS Thayer, LLC for audit-related violations. The complaint cites that action, together with SEC commentary about the role of gatekeepers such as auditors and underwriters, as part of its broader theory of liability.

Market Reaction

Concorde International Group, Ltd.’s stock price surged from its April 21, 2025 IPO price of $4.00 to an all-time intraday high of $31.06 on July 9, 2025, despite no fundamental news justifying the spike. On July 10, 2025, following exposure of the pump-and-dump scheme, Concorde International Group, Ltd.’s share price abruptly crashed approximately 80% to close at $5.66, down from the previous day’s closing price of $28.18. Since the crash, the company’s share price has continued to decline to approximately $2.00, representing a loss of over 93% from the peak and 50% below the IPO price, leaving retail investors with steep losses.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Concorde International Group, Ltd. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Concorde International Group, Ltd. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
SES Shareholders - Lead Plaintiff Deadline: June 26, 2026

SES AI Corporation Class Action Lawsuit – SES

 

SES AI Class Action Summary

Company

SES AI Corporation (NYSE: SES)

Lead Plaintiff Deadline

June 26, 2026

Class Period

January 29, 2025 – March 4, 2026

Stock Drop

March 5, 2026 – SES fell $0.63 (36.8%) to $1.08

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against SES AI Corporation (NYSE: SES) and its CEO Qichao Hu on behalf of investors who purchased SES AI securities between January 29, 2025 and March 4, 2026. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements about SES AI's business prospects, overstating the expected results of deals with companies that had limited or no meaningful operations, while concealing material logistics constraints that impacted fourth quarter 2025 revenues. When the Company reported fourth quarter 2025 results on March 4, 2026 and issued 2026 revenue guidance of $30 million to $35 million, far below the $51.67 million analysts expected, the stock plunged. On March 5, 2026, SES shares fell $0.63 per share, or 36.8%, to close at $1.08. Investors allege this decline caused losses for shareholders who purchased SES securities at artificially inflated prices.

Company Profile

SES AI Corporation is a developer and manufacturer of AI-enhanced lithium-metal and lithium-ion rechargeable battery technologies and battery materials for energy storage systems, urban air mobility, drones, robotics, electric vehicles, and other applications. The Company is incorporated in Delaware with its head office in Woburn, Massachusetts, and its common stock trades on the New York Stock Exchange under the ticker symbol SES.

Class Period

January 29, 2025 – March 4, 2026, inclusive.

Investors who purchased or acquired SES AI Corporation (SES) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that SES AI Corporation and its CEO Qichao Hu engaged in a scheme to artificially inflate the Company's stock price by announcing deals with business partners that lacked the capacity to generate meaningful revenue, while simultaneously promoting an AI platform called "Molecular Universe" whose commercial viability was allegedly overstated. According to the lawsuit, defendants made materially false and misleading statements beginning on January 29, 2025, when SES AI announced a memorandum of understanding with AISPEX, a Texas-based retail energy provider, targeting up to $45 million in revenue for battery energy storage system solutions at a crypto mining site in Texas. The complaint alleges this announcement materially overstated the likelihood of long-term revenues because AISPEX did not have any meaningful crypto mining operations in Texas. A December 2025 short-seller report by Wolfpack Research later revealed that AISPEX's listed headquarters was a "ramshackle building surrounded by shipping containers" bearing the signage of a different company, and that no progress had been made on the deal.

On the Company's fourth quarter 2024 earnings call on February 25, 2025, Defendant Hu reiterated the AISPEX deal and highlighted a "significant purchase order" with Data Blanket, an AI drone startup, for lithium-metal cells. The complaint alleges these statements were materially false because SES AI never actually delivered any product to Data Blanket, which the lawsuit describes as a small startup with only a handful of employees and limited business capacity. The Company also announced the completion of its acquisition of Shenzen UZ Energy Co., Ltd. in September 2025, stating it positioned SES AI to become "an active player in the global $300 billion ESS market." According to the complaint, this statement was materially misleading because UZ Energy was a low-margin business with very little U.S. presence. Its U.S.-related entity reportedly shared an address with two other companies, and its registered agent had been sued for allegedly helping launder money as part of a billion-dollar Ponzi scheme.

The complaint further alleges that SES AI's October 2025 announcement of a joint venture with Hisun New Energy Materials to commercially supply electrolyte materials discovered by Molecular Universe was materially false because Hisun had no manufacturing capacity within the United States. According to the Wolfpack Research report, Hisun's planned Texas facility site remained undeveloped swampland, its listed corporate address was a residential home, and it appeared to have only one U.S. employee. More broadly, the complaint alleges that SES AI created an appearance of revenue for Molecular Universe through circular transactions, buying equipment from companies in exchange for those companies buying Molecular Universe licenses. The complaint also cites a former employee who characterized the AI platform as "kind of a toy" with limited practical value due to a major bottleneck at the synthesis and testing stage. The complaint also alleges that SES AI's Q3 2025 quarterly report, which included Sarbanes-Oxley certifications signed by Defendant Hu, contained materially misleading risk disclosures that failed to acknowledge logistics constraints the Company knew were already materially impacting fourth quarter revenues. As late as January 16, 2026, at the Needham Growth Conference, Defendant Hu discussed the Company's revenue guidance and growth prospects without disclosing these logistics issues. Notably, the complaint alleges that SES AI's Chief Science Officer, Dr. Hong Gan, sold 500,000 shares of company stock for over $1 million in proceeds in November 2025 and January 2026, shortly after and during the period in which these alleged misrepresentations were being made.

The Truth Emerges

The first significant challenge to defendants' narrative came on December 9, 2025, when Wolfpack Research published a detailed short-seller report alleging that SES AI had announced "phantom deals" with entities lacking substantial operations and had promoted Molecular Universe to distract from the impending loss of major OEM customers Honda and Hyundai. The report documented site visits to AISPEX's headquarters, Hisun's purported facility location, and UZ Energy's U.S. address, finding a pattern of business partners whose physical presence and operational capacity did not match SES AI's public representations. A former employee quoted in the report described Molecular Universe subscriptions as effectively rebates on equipment purchases rather than genuine demand for the product.

The full extent of the alleged misrepresentations became clear on March 4, 2026, when SES AI held its fourth quarter earnings call. CFO Jing Nealis disclosed that logistics constraints had delayed shipments at the end of the year, pushing approximately $1.5 million of revenue into the first quarter of 2026, constraints that the complaint alleges the Company knew about but concealed during Defendant Hu's January 2026 conference appearance. More critically, the Company issued 2026 revenue guidance of $30 million to $35 million, dramatically below the $51.67 million Wall Street analysts had expected, confirming concerns about the pace and sustainability of commercialization that defendants' prior statements had obscured.

Market Reaction

The market reaction to SES AI's disappointing fourth quarter results and weak 2026 guidance was severe. On March 5, 2026, SES shares fell $0.63 per share, or 36.8%, to close at $1.08. Financial publication Benzinga reported that shares were "trading sharply lower" after the Company "posted mixed fourth-quarter results and issued a 2026 sales outlook that trailed Wall Street expectations," noting that the below-consensus guidance raised "concerns about the pace of commercialization" for SES AI's energy storage systems, drone battery, and materials businesses.

Next Steps

●       Lead Plaintiff Deadline: June 26, 2026

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in SES AI Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against SES AI Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
RGC Shareholders - Lead Plaintiff Deadline: June 23, 2026

Regencell Bioscience Holdings Limited Class Action Lawsuit – RGC

Regencell Class Action Summary

Company

Regencell Bioscience Holdings Limited (NASDAQ: RGC)

Lead Plaintiff Deadline

June 23, 2026

Class Period

October 28, 2024 – October 31, 2025

Stock Drop

November 3, 2025 – RGC fell $3.09 (18.56%) to $13.56

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Regencell Bioscience Holdings Limited (NASDAQ: RGC) and certain of its top officials on behalf of investors who purchased or acquired Regencell securities between October 28, 2024 and October 31, 2025. The complaint alleges that defendants made materially false and misleading statements by downplaying the company's vulnerability to market manipulation and the resulting risks to investors, even as RGC's share price surged nearly 48,650% during the Class Period without any corresponding change in business fundamentals. The truth began to emerge on October 31, 2025, when Regencell disclosed that it had received a subpoena from the U.S. Department of Justice indicating a federal investigation into trading in its ordinary shares. On this news, RGC shares fell $3.09 per share, or 18.56%, to close at $13.56 on November 3, 2025, causing significant losses to investors.

Company Profile

Regencell Bioscience Holdings Limited is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine for the treatment of attention-deficit/hyperactivity disorder and autism spectrum disorder. According to the complaint, the company, which has been publicly listed on the NASDAQ since July 2021, has twelve employees, no approved or salable products, no revenue, and has incurred operating losses since its formation. The complaint further alleges that the company reported research and development costs of only $0.95 million and $1.07 million for the fiscal years ended June 30, 2025 and 2024, respectively. Regencell is a controlled company under NASDAQ rules, with approximately 88.8% of its shares held by directors and executive officers, the vast majority by its founder, Chairman, and CEO, Defendant Yat-Gai Au.

Class Period

October 28, 2024 – October 31, 2025, inclusive.

Investors who purchased or acquired Regencell Bioscience Holdings Limited (RGC) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company's business, operations, and compliance policies by failing to disclose that Regencell was vulnerable and subject to market manipulation. According to the complaint, this alleged manipulation drove extraordinary volatility in RGC shares. The stock generally traded at less than $0.30 per share from the start of the Class Period through mid-March 2025 before allegedly surging to a high of $78.00 per share on June 17, 2025, representing a 48,650% increase. Despite having no revenue and no approved products, Regencell had a market value of approximately $14 billion as of the time of the complaint's filing, larger than all but 20 of the 261 companies in the Nasdaq Biotechnology Index, according to the complaint and The Wall Street Journal’s January 2026 reporting.

The complaint alleges that Regencell's SEC filings, including its 2024 annual report on Form 20-F filed during post-market hours before October 28, 2024, and its interim financial statements filed on June 30, 2025, contained only generic, catch-all risk warnings about potential share price volatility that were not tailored to the actual known risks. Rather than disclose the company's susceptibility to market manipulation, defendants attributed the extreme price swings primarily to short-selling activity, potential "short squeezes," and unidentified third-party news and social media activity. The Individual Defendants, CEO Yat-Gai Au and Financial Controller Michelle Chan, signed Sarbanes-Oxley certifications attesting that these filings did not contain untrue statements of material fact or omit material facts necessary to make the statements not misleading.

Plaintiffs allege that defendants knew or recklessly disregarded that these disclosures were inadequate. Defendant Au owned in excess of 80% of Regencell's ordinary shares at all relevant times, meaning the massive rise in share price produced an enormous increase in his personal net worth and, according to the complaint, made him undoubtedly highly attuned to significant fluctuations in the stock price. The complaint further alleges that by concealing the company's vulnerability to manipulation, defendants failed to comply with SEC Item 105, which requires disclosure of material risk factors, and Item 303, which requires disclosure of known trends or uncertainties likely to have a material impact on business results. The resulting volatility exposed investors to significant financial risk and subjected Regencell to a heightened risk of regulatory scrutiny and enforcement action.

The Truth Emerges

On October 31, 2025, during post-market hours, Regencell filed its annual report on Form 20-F for the fiscal year ended June 30, 2025. For the first time, the filing disclosed that "following recent volatility in the market for our Ordinary Shares, the Company received correspondence and a subpoena from the U.S. Department of Justice, indicating that the DOJ is conducting an investigation into the trading in our Ordinary Shares." The company revealed that the DOJ had requested production of documents and communications concerning corporate operational, financial, and accounting matters.

Regencell further disclosed that it expected to "continue to incur significant legal costs and other expenses in connection with responding to the investigation" and acknowledged that it "may be required to pay fines, penalties, damages or settlement costs in excess of our insurance coverage, if any, related to the investigation." The company also warned that the investigation could result in administrative, injunctive, or other proceedings against the company and its directors, officers, or employees. According to the complaint, this disclosure revealed that the company's prior framing of the volatility as primarily a product of short squeezes and third-party media activity had omitted the material fact that Regencell was subject to a federal investigation into the trading in its ordinary shares.

Market Reaction

Following the October 31, 2025 disclosure of the DOJ investigation, Regencell's ordinary shares fell $3.09 per share, or 18.56%, closing at $13.56 per share on November 3, 2025, the first trading day after the after-hours filing. This decline reflected the market's absorption of the federal investigation and the associated risks of fines, penalties, and enforcement action. The drop came after a Class Period in which RGC shares had already plummeted from their June 17, 2025 high of $78.00 per share, and the November 3 closing price represented a steep decline from the levels at which many investors had purchased shares during the period of extreme volatility.

Next Steps

●       Lead Plaintiff Deadline: June 23, 2026

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Regencell Bioscience Holdings Limited which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Regencell Bioscience Holdings Limited. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
GLOB Shareholders - Lead Plaintiff Deadline: June 23, 2026

Globant S.A. Class Action Lawsuit – GLOB

Globant Class Action Summary

Company

Globant S.A. (NYSE: GLOB)

Lead Plaintiff Deadline

June 23, 2026

Class Period

February 15, 2024 – August 14, 2025

Stock Drop

February 21, 2025 – GLOB fell $58.45 (27.8%) to $151.72; May 16, 2025 – GLOB fell $31.37 (23.6%) to $101.47; August 15, 2025 – GLOB fell $11.66 (14.9%) to $66.46

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Globant S.A. (NYSE: GLOB), its CEO Martin Migoya, CFO Juan Ignacio Urthiague, and former COO Patricia Pomies. The lawsuit covers investors who purchased or acquired Globant common stock between February 15, 2024 and August 14, 2025, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint alleges that defendants made materially false and misleading statements about the success of Globant's $1 billion strategic pivot to Latin America, concealing declining demand, client defections, project cancellations, and employee wage freezes that were undermining the Company's operations in the region. As the truth about these failures emerged over three corrective disclosures in 2025, Globant's stock price collapsed from over $210 per share to $66.46 per share, causing significant losses for investors.

Company Profile

Globant S.A. is a Luxembourg-incorporated international technology services company that provides digital consulting, software development, and IT outsourcing services to multinational corporations across a variety of sectors. The Company was founded in Argentina, maintains a workforce largely based in Latin America, and traditionally derived most of its revenue from U.S. clients before announcing a $1 billion strategic pivot to expand its Latin American business in mid-2023.

Class Period

February 15, 2024 – August 14, 2025, inclusive.

Investors who purchased or acquired Globant S.A. (GLOB) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the Class Period, Globant and its senior executives painted a consistently optimistic picture of the Company's Latin American expansion to investors. Beginning with the Q4 2023 earnings call on February 15, 2024, CEO Martin Migoya described Globant's "prominence" in Latin America as "particularly beneficial" and highlighted "significant investments in Mexico and Brazil," which together accounted for 38% of the Company's regional revenue. CFO Juan Ignacio Urthiague told investors the Company was "very confident about our ability to grow in Latin America" and emphasized that Brazil and Mexico represented opportunities to "significantly expand" Globant's presence. In the Company's Annual Report filed February 29, 2024, Globant described employee retention as "one of our main priorities and a key driver of operational efficiency and productivity" and emphasized its strategy of expanding its global delivery footprint to "gain access to additional pools of talent."

According to the complaint, these statements were materially false and misleading. In reality, as alleged in the complaint, Globant's Latin American strategy was failing. The Company was facing declining demand for its services, client defections, and project cancellations across the region. Globant's high-profile December 2023 acquisition of Iteris, a Brazilian digital consulting firm, was troubled, as former Iteris clients allegedly left because of Globant's high hourly rates, and the Company allegedly failed to properly integrate Iteris employees, who never received promised salary and benefit increases. Meanwhile, Globant had frozen wages for employees in Mexico and Argentina beginning in late 2023. Given the high inflation rates in those countries, particularly Argentina, which experienced double-digit inflation, these wage freezes effectively amounted to wage cuts, triggering widespread employee unrest that further degraded the Company’s ability to deliver quality services to clients.

The complaint alleges that defendants continued to conceal these problems through successive quarterly earnings calls. On the Q1 2024 call, Migoya described Globant as the "employer of choice" in Latin America and claimed the Company was in a "forefront position, outpacing other players in the industry." Urthiague told investors that Argentine salaries had experienced "a very good impact" and that the Company was "not expecting big changes," while Argentine employees' purchasing power was being eroded by frozen wages and persistent inflation. On the Q2 2024 call, COO Patricia Pomies stated that demand was "very, very high" and that the Company was "continu[ing] hiring in many of the countries," while Urthiague described Latin America as "a great place to be." By the Q3 2024 call in November, Pomies claimed the Company was "slightly growing year-over-year" in Latin America and would "start growing faster," while in reality the Computer Trade Association had formally petitioned Globant's CEO for urgent salary increases and workers alleged the Company was blocking unionization efforts. According to the complaint, defendants knew or recklessly disregarded that these positive representations were materially misleading because they had access to internal information about the deteriorating conditions in Latin America, including declining client demand, the wage freezes, employee unrest, and the failure of the Iteris acquisition.

The Truth Emerges

The truth about Globant's Latin American operations emerged through a series of disclosures in 2025. On February 20, 2025, the Company reported Q4 2024 results that missed guidance, revealing a 1.3% decrease in Latin American revenue and offering more muted Q1 2025 guidance. On the earnings call, Migoya acknowledged for the first time that the situation in Latin America during 2024 had been "a little bit rocky" due to "political turmoil and different things" in Brazil and Colombia, while Urthiague pointed to "a lot of political noise in Q4." This was the first time Globant gave investors any indication that its Latin American expansion had encountered significant problems during 2024.

On May 15, 2025, the Company reported disappointing Q1 2025 results that disclosed further deterioration. Globant acknowledged "a challenging macroeconomic and geopolitical context" affecting spending patterns among its largest Latin American customers and revealed that Latin American revenue had declined 9% year-over-year, "with notable contractions in Mexico and Brazil." Migoya conceded that "growth in some countries in Latin America [was] lower than expected," while the Company stated bluntly that "Mexico [is] suffering. Brazil is suffering." The full extent of the failures was revealed on August 14, 2025, when Globant reported Q2 2025 results disclosing that it had reduced headcount by approximately 1,000 employees and taken a $47.6 million restructuring charge. On the earnings call, defendants admitted that headcount in Latin America had been declining "for a number of quarters" and discussed the "deterioration" in Brazil and Mexico throughout 2024 and into 2025, a stark contradiction of the Company's prior statements about growth and expansion in those markets.

Market Reaction

Globant's stock price suffered three sharp declines as the truth about its Latin American operations reached the market. Following the February 20, 2025 disclosures, GLOB fell $58.45 per share, a decline of nearly 28%, from a closing price of $210.17 on February 20 to $151.72 on February 21, 2025. The May 15, 2025 disclosures triggered a further decline of $31.37 per share, more than 23%, with the stock falling from $132.84 to $101.47 on May 16, 2025. The August 14, 2025 revelations drove the stock down an additional $11.66 per share, a decline of nearly 15%, from $78.12 to $66.46 on August 15, 2025. In total, GLOB's stock price declined from $210.17 per share before the first corrective disclosure to $66.46 per share after the final disclosure, a cumulative loss of approximately 68% across the three corrective events.

Next Steps

●       Lead Plaintiff Deadline: June 23, 2026

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Globant S.A. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Globant S.A. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
LKQ Shareholders - Lead Plaintiff Deadline: June 22, 2026

LKQ Corporation Class Action Lawsuit – LKQ

LKQ Class Action Summary

Company

LKQ Corporation (NASDAQ: LKQ)

Lead Plaintiff Deadline

June 22, 2026

Class Period

February 27, 2023 – July 23, 2025

Stock Drop

April 23, 2024 – LKQ fell $7.28 (14.9%); July 25, 2024 – LKQ fell $5.53 (12.4%); April 24, 2025 – LKQ fell $4.87 (11.6%); July 24, 2025 – LKQ fell $6.88 (17.8%)

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against LKQ Corporation and certain of its current and former senior executives by the City of Miami General Employees' & Sanitation Employees' Retirement Trust. The lawsuit covers investors who purchased or acquired LKQ common stock between February 27, 2023 and July 23, 2025, inclusive. The complaint alleges that defendants made materially false and misleading statements about the success and strategic benefits of LKQ's approximately $2.1 billion acquisition of Uni-Select, including its U.S. subsidiary FinishMaster, while concealing that FinishMaster was losing major customers and market share from the time the acquisition was announced. As the truth about deteriorating performance in LKQ's North American segment emerged through a series of disclosures between April 2024 and July 2025, LKQ's stock price suffered cumulative declines totaling over $24 per share, causing significant losses for investors.

Company Profile

LKQ Corporation is a global distributor of alternative collision replacement parts, recycled engines, and other vehicle components for the repair of automobiles, headquartered in Antioch, Tennessee. The Company's common stock trades on the NASDAQ under the ticker symbol LKQ.

Class Period

February 27, 2023 – July 23, 2025, inclusive.

Investors who purchased or acquired LKQ Corporation (LKQ) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that beginning on February 27, 2023, when LKQ announced a definitive agreement to acquire competitor Uni-Select for approximately $2.1 billion, defendants launched a campaign of materially false and misleading statements about the acquisition's strategic value. Uni-Select's U.S. subsidiary, FinishMaster, operated approximately 200 automotive refinish and painting service locations and accounted for roughly 40% of Uni-Select's annual revenue. In its press release announcing the acquisition, LKQ represented that the deal was a "compelling strategic fit" that would "enhance LKQ's business and drive profitable growth" with "minimal integration risk." Defendant Zarcone, then CEO, further assured analysts that LKQ was "highly confident" it would capture $55 million in cost synergies within three years.

As the integration progressed through 2023 and into 2024, defendants allegedly continued to misrepresent FinishMaster's performance. On the October 2023 third-quarter earnings call, after the acquisition closed in August 2023, Defendant Zarcone described the deal as a "bespoke and highly synergistic opportunity" that would "further widen the competitive moat around our North American business." On the same earnings call, Defendant Rick Galloway, CFO, told investors the team was "accelerating synergies related to FinishMaster branches" and expressed confidence the transaction would be accretive in 2024. By February 2024, Defendant Justin Jude, who would succeed Zarcone as CEO, declared the integration was "ahead of schedule" and that LKQ was "confident in our ability to exceed the $55 million of synergies previously disclosed." Even on April 23, 2024, the same day LKQ slashed its financial guidance, Jude insisted the acquisition would "enable us to widen the moat around our North American business and capitalize on revenue synergies."

According to the complaint, these statements were false because FinishMaster was losing major customers and market share from the time the acquisition was first announced, and those losses only worsened as the integration proceeded. LKQ later revealed in October 2024 that customer losses began "pre-acquisition or pre-closing and leading into post-acquisition." The complaint alleges defendants knew or recklessly disregarded these facts. Defendant Zarcone discussed trends in FinishMaster's customer base as early as October 2023, acknowledging the team had a full picture of the business's records, yet failed to disclose the customer attrition. Zarcone, who oversaw the acquisition and departed in June 2024 as the truth began surfacing, sold over $14 million of his personally held LKQ shares. After each partial disclosure, defendants allegedly continued to reassure investors, claiming FinishMaster had "helped improve our margins," that business had "stabilized," and that the integration delivered "a higher level of synergies than originally planned," even as FinishMaster's deterioration continued to erode LKQ's North American segment results.

The Truth Emerges

The truth about FinishMaster's deteriorating performance emerged through a series of disclosures spanning more than a year. On April 23, 2024, LKQ lowered both its revenue and earnings guidance for fiscal year 2024, attributing the reduction to worsening performance in its North American segment, where FinishMaster was being integrated. The Company blamed slowing demand and warmer weather, but simultaneously announced the departure of CEO Zarcone, who had overseen the acquisition. On July 25, 2024, LKQ reported disappointing second-quarter 2024 earnings, revealing it had missed the reduced revenue targets set only one quarter earlier, and further cut its financial guidance. Then, on October 24, 2024, the Company made its most direct admission: FinishMaster's recent earnings misses were driven by significant customer losses that began before the acquisition even closed. Defendants acknowledged these losses started "pre-acquisition or pre-closing and leading into post-acquisition," directly contradicting months of reassurances about the deal's strategic benefits.

Despite these admissions, defendants continued to misrepresent the trajectory of the business. As late as February 2025, Defendant Jude boasted that the North American team had delivered the integration "faster than expected" with "a higher level of synergies than originally planned." On April 24, 2025, however, LKQ revealed that its Wholesale North America segment missed quarterly revenue targets by approximately $200 million and missed adjusted EBITDA margin targets by $24 million, suffering a year-over-year EBITDA decline of 9%, as competitors continued to take market share by undercutting LKQ on price. Finally, on July 24, 2025, LKQ reported that the segment's margin deterioration had continued, with EBITDA targets missed by approximately $20 million and a year-over-year EBITDA decline of 11%, driven predominantly by business losses from increased competition.

Market Reaction

LKQ's stock price suffered a series of significant declines as the scope of FinishMaster's customer losses and the deterioration of the North American segment became clear. On April 23, 2024, following the lowered guidance and CEO departure announcement, LKQ shares fell $7.28 per share, or 14.9%. On July 25, 2024, after the Company missed its already-reduced revenue targets and further cut guidance, the stock dropped another $5.53 per share, or 12.4%. On April 24, 2025, when LKQ disclosed that its North American segment had missed revenue targets by approximately $200 million and EBITDA margin targets by $24 million, shares declined $4.87 per share, or 11.6%. The final disclosure on July 24, 2025, revealing continued margin deterioration and an 11% year-over-year EBITDA decline driven by competitive losses, sent the stock down $6.88 per share, or 17.8%. In total, these corrective disclosures resulted in cumulative per-share declines exceeding $24.

Next Steps

●       Lead Plaintiff Deadline: June 22, 2026

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in LKQ Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against LKQ Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
BW Shareholders - Lead Plaintiff Deadline: June 15, 2026

Babcock & Wilcox Enterprises Class Action Lawsuit – BW

Babcock & Wilcox Class Action Summary

Company

Babcock & Wilcox Enterprises, Inc. (NYSE: BW)

Lead Plaintiff Deadline

June 15, 2026

Class Period

November 5, 2025 – March 11, 2026

Stock Drop

March 12, 2026 – BW fell $1.71 (11.59%) to $13.05

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Babcock & Wilcox Enterprises, Inc. (NYSE: BW) and two of its senior executives in the United States District Court for the Northern District of Ohio on behalf of investors who purchased or acquired BW securities between November 5, 2025 and March 11, 2026. The complaint alleges that defendants made materially false and misleading statements about the company's business prospects by repeatedly touting a purported $2.4 billion power generation contract without disclosing that BW's largest shareholder, BRC Group Holdings, stood on both sides of the transaction and maintained close ties to BW's counterparty. When a short seller report exposed these undisclosed relationships and questioned whether BW would ever recognize revenue from the contract, BW's stock price fell $1.71 per share, or 11.59%, to close at $13.05 on March 12, 2026, causing significant losses for investors who purchased shares at artificially inflated prices.

Company Profile

Babcock & Wilcox Enterprises, Inc., along with its subsidiaries, delivers energy and emissions-control products and services to industrial, electric utility, municipal, and other customers across the United States, Canada, the United Kingdom, Indonesia, and the Philippines. The company's common stock, 6.50% senior notes due 2026, and 7.75% Series A cumulative perpetual preferred stock trade on the New York Stock Exchange under the ticker symbols BW, BWNB, and BW PRA, respectively.

Class Period

November 5, 2025 – March 11, 2026, inclusive.

Investors who purchased or acquired Babcock & Wilcox Enterprises, Inc. (NYSE: BW) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

Allegations

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements about the value and legitimacy of a major power generation contract that BW presented as a transformational entry into the AI data center power supply market. On November 4, 2025, the company announced a limited notice to proceed for a project valued at over $1.5 billion to deliver one gigawatt of power for an AI factory owned by Applied Digital Corporation. Defendant Kenneth Young, BW's Chairman and CEO, described the deal's impact as "profound," claiming it added over $3 billion to the company's pipeline and brought the total global pipeline to over $10 billion. Defendants simultaneously entered into an at-the-market offering, raising $67.5 million in just two days, capital Defendants explicitly connected to the power generation deal.

According to the complaint, defendants continued to amplify the significance of the contract through multiple SEC filings, press releases, and an earnings conference call. During the Q3 earnings call on November 10, 2025, Defendant Young told investors that BW could recognize between 10% and 15% of the projected $1.5 billion contract value in fiscal year 2026, representing "significant upside" to the company's existing guidance of $70 million to $85 million in adjusted EBITDA. Chief Financial Officer Cameron Frymyer echoed these projections while also announcing that despite initially promising to pause the at-the-market offering, defendants had decided to resume share sales. On March 4, 2026, BW announced it had received full notice to proceed on a $2.4 billion design-build agreement with Base Electron, described as an independent power producer "backed by Applied Digital," sending BW shares up 45% in a single session.

The complaint alleges defendants failed to disclose critical facts that undermined the legitimacy of these representations. BW's largest shareholder, BRC Group Holdings (formerly B. Riley Financial), stood on both sides of the power generation contract: BRC's Co-CEO and Chairman, Bryant R. Riley, was also a director of Base Electron, and Base Electron's registered address matched BRC's headquarters rather than Applied Digital's. Base Electron itself was not incorporated until December 23, 2025, seven weeks after defendants announced the limited notice to proceed with a counterparty that did not yet exist. Meanwhile, Applied Digital's existing data center projects had already secured power through conventional grid agreements, calling into question whether Applied Digital even needed the power generation services BW would purportedly supply.

The complaint further alleges that the purported $2.4 billion contract value was misleading because only approximately $434 million was a fixed fee, while the remaining $1.96 billion consisted of variable charges and other undisclosed amounts. Moreover, Applied Digital could unilaterally terminate its guarantee of Base Electron's obligations under the agreement for as little as $50 million. BRC capitalized on the inflated stock price by selling its entire directly-held position in BW common stock for approximately $10.4 million at $9 per share, 140% above BW's closing price on the last trading session before the power generation deal was announced.

The Truth Emerges

On March 12, 2026, Wolfpack Research published a short report that exposed the undisclosed relationships at the heart of the power generation contract. The report revealed that BRC Co-CEO and Chairman Bryant Riley was a director of Base Electron, that Base Electron's registered address matched BRC's headquarters rather than Applied Digital's, and that Base Electron's articles of incorporation were not filed until December 23, 2025, weeks after BW had announced the limited notice to proceed. Wolfpack alleged that "the ultimate purpose of this deal may be to provide exit liquidity for" BRC, pointing to BRC's $10.4 million sale of its entire directly-held BW position at prices inflated by the very deal announcements defendants had promoted.

The Wolfpack report also undermined the premise that Applied Digital needed the power BW would purportedly generate. According to the report, Applied Digital's more established data center projects had already secured power through conventional grid agreements, and its prospective projects appeared likely to rely on existing grid power rather than new power plants that BW would construct. Combined with the revelation that Applied Digital could terminate its guarantee of Base Electron's obligations for as little as $50 million, the report's findings called into question whether BW was ever likely to recognize meaningful revenue from the contract that defendants had valued at $2.4 billion and used to justify a 470% increase in reported backlog.

Market Reaction

Following publication of the Wolfpack Research report on March 12, 2026, BW shares fell $1.71 per share, or 11.59%, to close at $13.05. The decline erased a significant portion of the gains BW had accumulated since defendants first announced the power generation deal on November 4, 2025, when the stock had last closed at $3.74 per share in the prior trading session. The stock had risen over 198% to $11.15 by February 3, 2026, and surged an additional 45% to $11.80 on March 4, 2026, when defendants announced the full $2.4 billion contract, gains that the complaint alleges were built on materially false and misleading statements about the nature and legitimacy of the underlying transaction.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Babcock & Wilcox Enterprises, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Babcock & Wilcox Enterprises, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Soleno Therapeutics, Inc. Class Action Lawsuit – SLNO

Introduction to Soleno Therapeutics, Inc. (SLNO) Securities Class Action Lawsuit

A securities class action lawsuit under the Securities Exchange Act of 1934 has been filed against Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain of its executives for the period between March 26, 2025 and November 4, 2025. Investors allege that the company and its officers made materially false and misleading statements regarding the safety profile and commercial viability of VYKAT XR (DCCR), the company’s only commercial product used to treat hyperphagia in patients with Prader-Willi syndrome.

According to the complaint, while executives touted a favorable safety profile with no new safety signals and strong commercial adoption, the company had allegedly concealed significant safety concerns including risks of excess fluid retention, pre-diabetes, diabetes, pulmonary edema, and congestive heart failure. As these safety issues emerged publicly through an investigative report, a patient death, and management admissions of commercial disruption, Soleno Therapeutics, Inc.’s stock price moved from over $90 per share to lows of less than $45 per share, reflecting a pattern of material stock price declines.

“Most SLNO shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Soleno Therapeutics, Inc. (SLNO) Securities Lawsuit Case Details

Case Name: City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., et al.

Case No.: 3:26-cv-01979

Jurisdiction: U.S. District Court, Northern District of California, San Francisco Division

Filed on: March 6, 2026

Soleno Therapeutics, Inc. (SLNO) Company Profile

Soleno Therapeutics (NASDAQ: SLNO), a rare disease focused biopharmaceutical company, is a pharmaceutical company focused on developing therapies for rare diseases and is headquartered in Redwood City, California. At the time of the complaint filing, the company’s only commercial product, reflecting its single-product company dependency, was diazoxide choline extended-release tablets (DCCR), marketed as VYKAT XR, for the treatment of hyperphagia in individuals with Prader-Willi syndrome, including hyperphagia in PWS.

Soleno Therapeutics, Inc. (SLNO) Securities Lawsuit Class Period

March 26, 2025 – November 4, 2025, inclusive.

All persons who purchased Soleno Therapeutics, Inc. common stock during the Class Period may be eligible to join the Soleno Therapeutics, Inc. (SLNO) class action lawsuit, including investors who purchased common stock on the NASDAQ (NASDAQ: SLNO).

Allegations in the Soleno Therapeutics, Inc. (SLNO) Securities Class Action Lawsuit

The complaint targets Soleno Therapeutics, Inc. and three of its executives: Anish Bhatnagar, Chief Executive Officer and Chairman of the Board; James Mackaness, Chief Financial Officer; and Meredith Manning, Chief Commercial Officer, alleging violations of the Securities Exchange Act of 1934. Investors allege that these defendants made materially false and misleading statements about the safety profile and commercial prospects of VYKAT XR throughout the class period and downplayed or concealed material safety concerns and related commercial risks.

On March 26, 2025, as the product received approval, by the Food and Drug Administration, CEO Bhatnagar emphasized on a conference call that the label “reflects VYKAT’s favorable safety and tolerability profile, contains no [box] warnings, no contraindications for diabetes, no exclusions for severity of hyperphagia, and no requirement for a risk evaluation and mitigation strategy or REMS program.”

Just weeks later on May 7, 2025, Bhatnagar highlighted in a press release that “the high level of interest that we are experiencing, as reflected in both patient start forms and unique prescribers, reflects the significant unmet need that VYKAT XR can address as a first-to-market treatment for this debilitating condition.” During the second quarter, Soleno Therapeutics, Inc. reported $32.7 million in revenue from DCCR sales, and by August 6, 2025, Bhatnagar told investors on a conference call that “discontinuation rates are substantially lower than what we saw even in clinical trials” and assured them that “we have not seen anything in the postmarketing setting that is different from the clinical trial setting. So there are no new safety signals,” while investors allege the company downplayed adverse events.

According to the complaint, these statements were materially false and misleading because the company’s Phase 3 clinical trial program had allegedly systematically downplayed, misrepresented, or concealed significant evidence of safety concerns potentially related to DCCR administration, including issues related to excess fluid retention in clinical trial participants, and other adverse events. The complaint alleges that DCCR posed materially greater safety risks than disclosed and had materially lower commercial viability due to undisclosed risks of significant and widespread adverse events, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout.

The Truth Emerges

The truth began to surface on August 15, 2025, when Scorpion Capital LLC published an extensively researched exposé, a 415-page report titled “Russian Roulette With Prader-Willi Children: How The Latest Rare Disease Price-Gouging Scheme Fleeced the FDA, Parents, And Its Own Study Investigators With A Worthless, Toxic Drug.” The report detailed problems with Soleno Therapeutics, Inc.’s clinical trial conduct, safety and efficacy concerns with DCCR, and patient reports of serious adverse reactions, with key trial investigators broadly rebuking VYKAT XR as a failure and looming safety disaster, including high risks of pre-diabetes, diabetes, pulmonary edema, and congestive heart failure, which plaintiffs allege helped reveal previously undisclosed safety concerns.

On September 10, 2025, Soleno Therapeutics, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission disclosing that a patient had died after taking DCCR, though the company stated that the treating physician and Soleno Therapeutics, Inc.’s own assessment concluded the death was not related to treatment with VYKAT XR.

Finally, on November 4, 2025, during an earnings call, CEO Bhatnagar admitted that the Scorpion Capital Report had caused a “disruption” in DCCR’s launch trajectory, signaling commercial launch disruption and concerns within the Prader-Willi syndrome community, with a lower number of patient start forms and increased discontinuations beginning after the report’s publication. These revelations directly contradicted the company’s prior assurances about VYKAT XR’s favorable safety profile, absence of new safety signals, strong commercial adoption, and low discontinuation rates. What executives had portrayed as a successful first-to-market treatment with robust demand was now revealed to face significant safety concerns and commercial headwinds.

Market Reaction

Following the August 15, 2025 Scorpion Capital Report, which alleged safety and clinical-trial concerns related to DCCR, Soleno Therapeutics, Inc.’s stock price (NASDAQ: SLNO) declined from more than $77 per share on August 14, 2025 to close at approximately $68 per share on August 18, 2025, nearly a 12% drop over two trading days on above-average trading volume.

After the September 10, 2025 disclosure of the patient death, the stock fell from more than $70 per share on September 9, 2025 to close at approximately $57 per share on September 11, 2025, approximately a 19% drop over two trading days on above-average trading volume, continuing a pattern of stock price declines following the disclosures described in the complaint. On November 5, 2025, following the company’s third quarter results and CEO Bhatnagar’s admission of commercial disruption along with a social media post about congestive heart failure, amplifying safety concerns, the stock plummeted from nearly $64 per share on November 4, 2025 to close at approximately $47 per share, a one-day drop of approximately 27% on above-average trading volume.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Frequently Asked Questions

What is the Soleno Therapeutics securities class action lawsuit about?

The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that Soleno Therapeutics, Inc. (NASDAQ: SLNO) and certain executives violated federal securities laws by making materially false and misleading statements about the safety profile of VYKAT XR (diazoxide choline extended-release tablets). According to the complaint, defendants allegedly concealed significant safety concerns identified during the Phase 3 clinical trial program for the company’s only commercial product, which is approved to treat hyperphagia in individuals with Prader-Willi syndrome.

What is the class period for the Soleno (SLNO) lawsuit?

The class period extends from March 26, 2025, through November 4, 2025. Investors who purchased Soleno common stock during this timeframe may be eligible to participate in the class action. The class period begins on the date the FDA approved VYKAT XR and ends when the company disclosed that a critical research report had caused disruption to the drug’s commercial launch trajectory.

What specific allegations does the complaint make against Soleno?

The complaint alleges that Soleno’s Phase 3 clinical trial program systematically:

  • Downplayed and concealed evidence of safety concerns related to DCCR administration
  • Failed to adequately disclose risks of excess fluid retention in clinical trial participants
  • Misrepresented the drug’s commercial viability given undisclosed adverse event risks

Plaintiffs allege these omissions caused the stock price to be artificially inflated during the class period.

Who are the defendants named in the Soleno securities lawsuit?

The complaint names Soleno Therapeutics, Inc. as a corporate defendant along with three individual defendants: Anish Bhatnagar (CEO and Chairman), James Mackaness (CFO), and Meredith Manning (Chief Commercial Officer). According to the complaint, these executives were directly involved in drafting, reviewing, and disseminating the allegedly false and misleading statements about VYKAT XR’s safety profile and commercial prospects.

What events allegedly revealed the truth about Soleno’s disclosures?

According to the complaint, the stock declined after several disclosures:

  • On August 15, 2025, Scorpion Capital published a detailed report alleging safety issues with VYKAT XR and problems with clinical trial conduct
  • On September 10, 2025, Soleno disclosed a patient death following DCCR treatment
  • On November 4, 2025, Soleno acknowledged the research report had disrupted the drug’s launch, with increased patient discontinuations

The complaint alleges Soleno stock fell approximately 50% from its class period high.

What safety concerns does the lawsuit allege were concealed?

The complaint alleges defendants failed to disclose risks including excess fluid retention, potential cardiac issues, and hyperglycemia associated with DCCR. According to the Scorpion Capital report cited in the complaint, trial investigators reportedly expressed concerns about edema, diabetes risk, and alleged pressure to downplay adverse effects during the clinical program. The complaint also references social media posts from parents reporting severe adverse reactions in their children following the drug’s commercial launch.

Did Soleno executives sell stock during the class period?

According to the complaint, significant insider sales occurred during the class period. The lawsuit alleges that on March 27, 2025, the day after FDA approval, CEO Bhatnagar sold over $47 million in Soleno stock, CFO Mackaness sold over $6 million, and CCO Manning sold over $3 million, all at prices around $72 per share. The complaint characterizes these sales as suspicious in timing and amount, executed at prices far exceeding where the stock traded at the end of the class period.

What is the Soleno Therapeutics class action about?

The lawsuit alleges Soleno (NASDAQ: SLNO) and certain executives made false statements about the safety of VYKAT XR, concealing risks identified during clinical trials. The complaint claims these omissions artificially inflated the stock price during the class period from March 26, 2025, to November 4, 2025.

Who can participate in the Soleno securities lawsuit?

Investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, may be eligible class members. The complaint was filed in the U.S. District Court for the Northern District of California on behalf of all such purchasers.

What allegedly caused Soleno’s stock to decline?

According to the complaint, the stock fell after an August 2025 research report alleged safety problems with VYKAT XR, a September 2025 patient death disclosure, and November 2025 acknowledgment that launch disruptions caused increased patient discontinuations.

What safety issues does the lawsuit allege?

The complaint alleges defendants concealed evidence of fluid retention, cardiac risks, and hyperglycemia associated with DCCR. Plaintiffs claim trial investigators reportedly expressed concerns about these issues and alleged pressure to downplay adverse effects.

Did Soleno insiders sell stock during the class period?

According to the complaint, company executives sold tens of millions of dollars in stock the day after FDA approval. The lawsuit alleges CEO Bhatnagar alone sold over $47 million at approximately $72 per share.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Soleno Therapeutics, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Soleno Therapeutics, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join RH Class Action Lawsuit: RH Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into RH (NYSE: RH) concerning potential violations of the federal securities laws.

On December 11, 2025, CEO Gary Friedman told investors that RH's fourth quarter outlook incorporated "an approximate negative 200-basis-point operating-margin impact from investments and startup costs to support our international expansion and a 170 basis point impact from tariffs net of mitigations." CFO Jack Preston later acknowledged that RH’s “[a]djusted operating margin of 11.6% was below the 12.5% midpoint of [its] guidance due to higher-than-forecasted tariff expense on prior-period special order and back-order sales delivered in the quarter and higher-than-expected tariffs opening expenses." The company's own CFO attributed the margin shortfall directly to tariff costs that exceeded what had been disclosed to investors. Separately, Friedman stated during the Q2 2025 earnings call on September 11, 2025: "Our outlook does not include any new tariffs as a result of the recently announced furniture investigation." The U.S. International Trade Commission subsequently moved forward with the investigation. The 170-basis-point tariff figure presented as a comprehensive accounting of the headwind did not reflect the scope of the exposure RH faced.

If you suffered a loss on your RH securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in RH which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against RH. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join JinkoSolar Holding Co., Ltd. Class Action Lawsuit: JKS Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into JinkoSolar Holding Co., Ltd. (NYSE: JKS) concerning potential violations of the federal securities laws.

During the Q1 2025 earnings call on April 29, 2025, Charlie Cao, the CFO of principal operating subsidiary, Jinko Solar Co., Ltd., told analysts: “We expect the gross margin to improve and slightly in the second quarter given the module price reaching upward trend with the push demand from China and other regions.” At the same time, the company acknowledged that average selling prices were under pressure and that a 145% U.S. tariff on Chinese solar goods was already under discussion during the call’s Q&A session. The filing did not quantify the expected margin impact of those tariff costs or the trajectory of module pricing declines.

By Q4 2025, revenue had fallen 34% year-over-year, and the company reported a GAAP net loss of $214.5 million — a swing from the positive outlook management had projected months earlier. The gap between the forward guidance and the reported result left investors holding shares purchased at prices that reflected an improving margin trajectory.

If you suffered a loss on your JinkoSolar Holding Co., Ltd. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in JinkoSolar Holding Co., Ltd. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against JinkoSolar Holding Co., Ltd. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
SMCI Shareholders - Lead Plaintiff Deadline: May 25, 2026

Super Micro Computer, Inc. Class Action Lawsuit – SMCI

Introduction to Super Micro Computer, Inc. (SMCI) Securities Class Action Lawsuit

A securities fraud class action has been filed against Super Micro Computer, Inc. (NASDAQ: SMCI), asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, in the U.S. District Court for the Northern District of California on behalf of investors who purchased or acquired the company’s securities between February 2, 2024 and March 19, 2026. Investors allege that Super Micro and its executives made materially false or misleading statements, and failed to disclose that a significant portion of the Company’s server sales were to China-based companies, that those transactions violated U.S. export control laws, and that there were material weaknesses in the Company’s controls to ensure compliance with those laws and regulations. On March 19, 2026, the U.S. Justice Department announced criminal indictments alleging that approximately $2.5 billion worth of servers housing U.S. artificial intelligence technology were diverted to customers in China in violation of U.S. export control laws. The next day, Super Micro’s stock fell 33.3% to $20.53 per share amid unusually heavy trading.

Super Micro Computer, Inc. (SMCI) Securities Lawsuit Case Details

Case Name: Apurva Bhuva v. Super Micro Computer, Inc., et al.

Case No.: 5:26-cv-02606

Jurisdiction: U.S. District Court, Northern District of California

Filed on: March 25, 2026

Super Micro Computer, Inc. (SMCI) Company Profile

Super Micro Computer is headquartered in San Jose, California, and publicly traded on the Nasdaq exchange under the ticker NASDAQ: SMCI. The company designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence, data center, and cloud solutions customers. The company’s flagship products are servers that integrate Nvidia graphics processing units and are subject to strict U.S. export controls, including regulations governing U.S.-origin GPU technology administered by the U.S. Department of Commerce barring their sale to China without a license.

Super Micro Computer, Inc. (SMCI) Securities Lawsuit Class Period

February 2, 2024 – March 19, 2026, inclusive.

All persons and entities that purchased or otherwise acquired Super Micro securities, including common stock traded on the Nasdaq exchange during the Class Period and were damaged thereby may be eligible to join the Super Micro Computer, Inc. (SMCI) class action lawsuit.

Allegations in the Super Micro Computer, Inc. (SMCI) Securities Class Action Lawsuit

The complaint alleges that Super Micro, CEO Charles Liang, and CFO David Weigand made materially false and misleading statements during the Class Period while failing to disclose that a significant portion of server sales were to China-based companies, that those transactions violated U.S. export control laws, and that there were material weaknesses in the Company’s controls to ensure compliance with those laws and regulations. On April 30, 2024, CEO Charles Liang announced record third quarter revenue of $3.85 billion with year-over-year growth of 200%, attributing the success to strong demand for AI rack scale solutions and the company’s ability to expand its market leadership in AI infrastructure, while he and David Weigand certified the effectiveness of internal controls in SEC filings. The company continued celebrating explosive growth throughout 2024 and into 2025, even as Hindenburg Research published a report on August 27, 2024 highlighting ongoing internal control weaknesses, with Liang announcing on August 6, 2024 that fiscal 2024 revenue surged 110% year over year to $14.9 billion, driven by what he described as record demand for new AI infrastructures.

During this period, the complaint alleges that a significant portion of these celebrated sales were actually servers illegally diverted to companies based in China in violation of U.S. export control laws, including AI servers assembled in the United States with Nvidia GPUs that were routed through Southeast Asia to conceal their ultimate China destination. On August 5, 2025, Liang touted the company’s solid progress in fiscal year 2025, claiming 47% annual growth fueled by AI solution leadership across multiple customer segments including what he termed sovereign entities, while concealing a dependence on China-based sales for a significant portion of revenue. By November 4, 2025, Liang projected at least $36 billion in revenue for fiscal year 2026, citing a rapidly expanding order book that included more than $13 billion in Blackwell Ultra orders, which investors allege lacked a reasonable basis because export compliance controls were deficient. Throughout these announcements, investors allege that defendants concealed material weaknesses in the company’s controls to ensure compliance with applicable export control laws and regulations, even after Ernst & Young LLP resigned as the independent auditor on October 30, 2024 citing concerns about management integrity and board independence, all while the illegal sales scheme allegedly generated approximately $2.5 billion in revenue between 2024 and 2025.

The Truth Emerges

On March 19, 2026, after the market closed, the U.S. Justice Department announced the unsealing of an indictment against three individuals associated with Super Micro for engaging in a scheme to divert massive quantities of servers housing U.S. artificial intelligence technology containing Nvidia GPUs to customers in China in violation of U.S. export control laws by routing shipments through Southeast Asia. The announcement revealed that these activities were conducted to drive sales in violation of U.S. law, enabling the sale of approximately $2.5 billion worth of servers between 2024 and 2025, including more than $510 million diverted in a six-week period between April and May 2025. Super Micro confirmed that the charged individuals had been affiliated with the company, including co-founder Yih-Shyan Wally Liaw, who resigned from the board following the indictment, and reported that two employees were placed on administrative leave and one contractor’s relationship was terminated, and stated that Super Micro was not named as a defendant in the DOJ criminal case, while acknowledging the company had been cooperating fully with the government’s investigation.

These revelations followed the company’s prior statements celebrating record growth and market leadership and supported allegations that significant server sales were illegally diverted to China in violation of U.S. export control laws and that the company lacked adequate export compliance controls. The complaint alleges there were material weaknesses in the companys export compliance controls, and that, during the Class Period, executives highlighted a fast-growing order pipeline, artificially inflating the stock price and significant Blackwell Ultra demand exceeding $13 billion.

Market Reaction

On March 20, 2026, following the Justice Department’s announcement, Super Micro’s stock price (NASDAQ: SMCI) collapsed $10.26, or 33.3%, closing at $20.53 per share on unusually heavy trading volume, wiping out approximately $6.1 billion in market value. The single-day decline came as investors absorbed the DOJ’s disclosures about an alleged scheme to divert servers to China in violation of U.S. export control laws, including the sale of approximately $2.5 billion worth of servers between 2024 and 2025, and the criminal indictments of individuals associated with the company.

Next Steps

●      The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●      The Court will then consider motion for class certification.

●      The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Super Micro Computer, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Super Micro Computer, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Driven Brands Class Action Lawsuit - DRVN

Introduction to Driven Brands Holdings Inc. (DRVN) Securities Class Action Lawsuit

A securities fraud class action has been filed against Driven Brands Holdings Inc. (NASDAQ: DRVN) and certain of its officers and directors, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of all persons who purchased or otherwise acquired Driven Brands Holdings Inc. common stock between May 9, 2023, and February 24, 2026. Investors allege that the company misrepresented its financial condition and the effectiveness of its internal controls through a series of inaccurate financial reports, including its consolidated financial statements, filed with the Securities and Exchange Commission. 

On February 25, 2026, in a Form 8-K Current Report, the company revealed that material errors permeated nearly three years of financial statements, requiring comprehensive restatements across fiscal years 2023 and 2024 and all quarterly and year-to-date periods through September 2025. The stock declined (approximately 39.8%) on the disclosure as investors learned the financial statements they had relied upon required comprehensive restatements.

“Most DRVN shareholders never file or join the class action, which means they miss out on potential recovery funds,” said Attorney Joseph Levi.

Driven Brands Holdings Inc. (DRVN) Securities Lawsuit Case Details

Case Name: Clark v. Driven Brands Holdings Inc.

Case No.: 1:26-cv-01902

Jurisdiction: U.S. District Court, Southern District of New York

Filed on: March 9, 2026

Driven Brands Holdings Inc. (DRVN) Company Profile

Driven Brands Holdings Inc. is the largest automotive services company in North America, publicly traded on the NASDAQ as DRVN, operating approximately 4,900 locations across more than 15 countries. The company provides automotive aftermarket maintenance, car wash, collision, and glass services through major brands including Take 5 Oil Change, Meineke Car Care Centers, Maaco, and Auto Glass Now.

Driven Brands Holdings Inc. (DRVN) Securities Lawsuit Class Period

May 9, 2023-February 24, 2026, inclusive.

Investors who purchased or otherwise acquired Driven Brands Holdings Inc. common stock traded on NASDAQ: DRVN during the Class Period may be eligible to join the Driven Brands Holdings Inc. (DRVN) class action lawsuit.

DRVN-New-Case-Infographic.webp

Allegations in the Driven Brands Holdings Inc. (DRVN) Securities Class Action Lawsuit

The complaint targets Driven Brands Holdings Inc. and five executives who allegedly misled investors through material misstatements and omissions about the company's financial performance and internal controls throughout nearly three years of operations. Named as defendants are Jonathan Fitzpatrick, who served as Chief Executive Officer from 2012 through May 9, 2025; Michael F. Diamond, Chief Financial Officer from August 9, 2024, through the end of the class period; Michael Beland, Senior Vice President and Chief Accounting Officer from July 2021 to January 3, 2025; Daniel Rivera, who became President and Chief Executive Officer on May 9, 2025; and Rebecca Fondell, who assumed the role of Senior Vice President and Chief Accounting Officer on the same date.

According to the complaint, the company filed a series of condensed consolidated quarterly reports with the Securities and Exchange Commission that painted a picture of consistent revenue growth driven by same-store sales and net store expansion. On May 9, 2023, Fitzpatrick and Beland reported revenue increased 20% to $562 million in the first quarter. Three months later, on August 9, 2023, they announced revenue climbed 19% to $607 million in the second quarter. By November 9, 2023, they disclosed third-quarter revenue rose 12% to $581 million, continuing the narrative of steady growth. As late as November 5, 2025, Rivera and Fondell certified that the company's disclosure controls and procedures were designed effectively and would provide a reasonable level of assurance, while failing to disclose material weaknesses in internal controls over financial reporting.

The complaint alleges that Driven Brands later disclosed multiple accounting issues affecting its financial reporting, including lease accounting, cash reconciliation, expense classification, income tax provision, supply and other revenue recognition, fixed assets, cloud computing costs, lease cash application, and other balance-sheet and income-statement misclassifications. The complaint further alleges that the company identified improperly recognized revenue in its ATI business, primarily related to fiscal year 2025.

The Truth Emerges

On February 25, 2026, Driven Brands Holdings Inc. filed a Current Report on Form 8-K under the Securities Exchange Act revealing that two days earlier, on February 23, 2026, the Audit Committee of the Board of Directors had concluded there were material errors in the company's previously issued consolidated financial statements for fiscal years 2023 and 2024 and quarterly periods through September 27, 2025. 

The company announced that its consolidated financial statements for each of the quarterly and year-to-date periods within fiscal year 2024 as well as the quarterly and year-to-date periods through September 27, 2025, should not be relied upon, constituting a multi-year financial restatement, and delayed filing its 2025 Form 10-K. Management admitted it had identified material weaknesses in the company's internal control over financial reporting, concluding that internal controls and disclosure controls were not effective as of December 27, 2025.

These revelations contradicted nearly three years of financial reporting and internal control certifications made in SEC filings. Every quarterly revenue growth figure reported from May 2023 through November 2025 was now suspect, and the assurances about effective disclosure controls that Rivera and Fondell had provided just months earlier proved unfounded.

Market Reaction

The market reacted swiftly to the disclosure. On February 25, 2026, Driven Brands Holdings Inc.'s stock opened at $9.99 per share for DRVN on the NASDAQ, down from its closing price of $16.61 on February 24, 2026, a decline of $6.62 (approximately 39.8%). That single-day drop reflected investor’s reaction to the company’s disclosure that its financial statements for 2023, 2024, and quarterly periods in 2025 should not be relied upon and would be restated, triggering investor losses and securities litigation.

Next Steps

●        The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●        The Court will then consider motion for class certification.

●        The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Driven Brands Holdings Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Driven Brands Holdings Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join The Simply Good Foods Company Class Action Lawsuit: SMPL Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into The Simply Good Foods Company (NASDAQ: SMPL) concerning potential violations of the federal securities laws.

During the Q4 2025 earnings call on October 23, 2025, CEO Geoff Tanner told investors: "we’re confident our gross margins will improve beginning modestly in Q3 and more meaningfully into Q4,” and “are confident we will work through these headwinds as we continue to evolve the company." Simply Good Foods reaffirmed its fiscal 2026 guidance when reporting Q1 2026 earnings, expecting flat net sales at the midpoint and gross margin declines between 100 and 150 basis points. When the Q2 results were reported, the company disclosed a 9.4% year-over-year revenue decline and a similar gross margin decline of 460 basis points for the quarter. Simply Good Foods subsequently cut FY 2026 revenue guidance to negative 7-10% growth and gross margin to a decline of 300 to 350 basis points in the year. The stock fell over 18% in a single session.

If you suffered a loss on your The Simply Good Foods Company securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in The Simply Good Foods Company which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against The Simply Good Foods Company. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
UHG Shareholders - Lead Plaintiff Deadline: June 09, 2026

United Homes Group Class Action Lawsuit – UHG

United Homes Class Action Summary

Company

United Homes Group, Inc. (NASDAQ: UHG)

Lead Plaintiff Deadline

June 9, 2026

Class Period

May 19, 2025 – February 22, 2026

Stock Drop

October 20, 2025 – UHG fell $2.23 (52.46%) to $2.03; November 6, 2025 – UHG fell $0.11 (7.6%) to $1.34; February 23, 2026 – UHG fell $1.23 (51.68%) to $1.15

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against United Homes Group, Inc. (NASDAQ: UHG) and certain of its current and former executives in the United States District Court for the Southern District of New York. The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased or acquired United Homes securities between May 19, 2025 and February 22, 2026. The lawsuit alleges that defendants made materially false and misleading statements by concealing that the Company's controlling shareholder, founder Michael Nieri, was pursuing a course of conduct designed to force a sale of the Company at a steep discount to shareholders, including by effectively driving the resignation of six of seven board members and leveraging his controlling interest to devalue the Company. When the full scope of Nieri's alleged scheme was revealed through a series of disclosures culminating in a February 2026 acquisition announcement at $1.18 per share, an over 50% discount to the prior trading price, United Homes' stock suffered devastating cumulative losses.

Company Profile

United Homes Group, Inc. is a residential home building company incorporated in Delaware and headquartered in Chapin, South Carolina. The Company's Class A common shares trade on the NASDAQ exchange under the ticker symbol UHG. As of April 2025, founder Michael Nieri and his family members held 100% of Class B shares, representing 79% of voting power, and 68.8% of Class A shares.

Class Period

May 19, 2025 – February 22, 2026, inclusive.

Investors who purchased or acquired United Homes Group, Inc. (UHG) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

Allegations

The complaint alleges that throughout the Class Period, defendants concealed that United Homes' founder, Executive Chairman, and controlling shareholder Michael Nieri intended to force a sale of the Company on terms detrimental to public investors. Beginning on May 19, 2025, the Company announced the formation of a special committee of independent directors to explore strategic alternatives "to maximize shareholder value," including a potential sale, asset disposition, or refinancing. Nieri publicly stated the Company was "committed to maximizing value for all of our shareholders." According to the complaint, these representations were materially false and misleading because they concealed Nieri's actual intentions and the actions he was taking to devalue the Company and engineer a forced sale.

The complaint further alleges that throughout the summer of 2025, the Company continued to present an image of good-faith strategic exploration. In its second quarter 2025 earnings release on August 7, 2025, CEO Jack Micenko highlighted operational progress and product initiatives, while the Company reiterated that the strategic alternatives review was ongoing and aimed at maximizing shareholder value. The Company's Form 10-Q filed August 8, 2025 affirmed effective internal disclosure controls and procedures, and included a risk factor warning that the strategic alternatives process "may not be successful[,]" a warning the complaint characterizes as misleading given what defendants allegedly knew about Nieri's plans. Throughout these disclosures, the complaint alleges defendants failed to reveal that Nieri was not acting in the best interests of the Company and its public investors.

At the core of the alleged scheme, the complaint contends that Nieri leveraged his 79% voting control to effectively force the resignation of the Company's independent directors when they attempted to check his authority. When the special committee concluded its review and unanimously determined that remaining independent was in shareholders' best interests, the dissident directors conditioned their continued service on Nieri stepping down as Executive Chairman and forgoing remaining compensation. Nieri refused, and six of seven board members resigned, leaving Nieri as the sole remaining director with control over the Company's fate. The complaint alleges this was not an unexpected governance crisis but rather the predictable result of Nieri's deliberate campaign to consolidate control and force a sale on his terms.

The Truth Emerges

The truth began to surface on October 20, 2025, when United Homes filed a Form 8-K revealing the outcome of the special committee's review. While the committee had unanimously concluded that continuing as an independent public company was in shareholders' best interests, the filing disclosed a dramatic corporate governance breakdown: the entire board, except Nieri, had either resigned immediately or announced their intention to resign by November 14, 2025, after Nieri refused to step down as Executive Chairman. The revelation that the Company's controlling shareholder had effectively driven out the independent board members who disagreed with him stunned the market.

The damage deepened on November 6, 2025, when the Company's third quarter earnings release revealed the operational fallout from the mass board resignations. United Homes disclosed it had been "engaged in discussions with various key counterparties, including its lenders, land banking partners, and insurers" about maintaining compliance with loan covenants and "the pressing need to identify replacement directors." The Company further reported a 29% year-over-year decline in home closings and a 23% decline in revenue. The subsequent Form 10-Q filed November 7, 2025 disclosed that key counterparties including auditors had "expressed concern regarding UHG's ongoing corporate governance" and warned that failure to seat replacement directors could result in NASDAQ delisting, inability to obtain audit opinions, and default under debt arrangements.

The full extent of the alleged scheme became clear on February 23, 2026, when United Homes announced it had agreed to become a wholly owned subsidiary of Stanley Martin Homes, LLC in an all-cash transaction valuing the enterprise at approximately $221 million. Shareholders would receive just $1.18 per share, an over 50% discount to the $2.38 closing price on the last trading day before the announcement. The complaint alleges this fire-sale acquisition was the culmination of Nieri's deliberate strategy to devalue the Company and force a sale that served his interests at the expense of public shareholders.

Market Reaction

United Homes' stock suffered three devastating declines as the truth emerged. On October 20, 2025, following disclosure of the mass board resignations and Nieri's refusal to step down, UHG shares fell $2.23 per share, or 52.46%, to close at $2.03 on unusually heavy trading volume. On November 6, 2025, after the Company revealed deteriorating financial results and significant operational difficulties stemming from the governance crisis, UHG fell an additional $0.11 per share, or 7.6%, to close at $1.34 on unusually heavy volume.

The most damaging blow came on February 23, 2026, when the Stanley Martin acquisition was announced at $1.18 per share. UHG shares fell $1.23, or 51.68%, to close at $1.15 on unusually heavy trading volume. The $1.18 deal price represented an over 50% discount to the prior day's $2.38 closing price, and a precipitous decline from the Class Period high of $4.49 reached on August 22, 2025.

Next Steps

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in United Homes Group, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against United Homes Group, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
UPST Shareholders - Lead Plaintiff Deadline: June 08, 2026

Upstart Holdings Class Action Lawsuit – UPST

Upstart Class Action Summary

Company

Upstart Holdings, Inc. (NASDAQ: UPST)

Lead Plaintiff Deadline

June 8, 2026

Class Period

May 14, 2025 – November 4, 2025

Stock Drop

November 5, 2025 – UPST fell $4.49 (9.71%) to $41.75

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Upstart Holdings, Inc. (NASDAQ: UPST) and several of its senior executives on behalf of investors who purchased or acquired Upstart securities between May 14, 2025 and November 4, 2025. The complaint, filedin the United States District Court for the Northern District of California, alleges that defendants made materially false and misleading statements about the accuracy and performance of the company's flagship AI underwriting model, Model 22, and its impact on loan approval rates, conversion rates, and revenue growth. According to the lawsuit, defendants concealed that Model 22 frequently overreacted to negative macroeconomic signals, producing overly conservative credit assessments that materially undermined Upstart's revenue results and rendered its repeatedly raised full-year 2025 revenue guidance unreliable. When these issues surfaced on November 4, 2025, during Upstart's third-quarter earnings release and conference call, the company's stock price fell $4.49 per share, or 9.71%, to close at $41.75 the following day, causing significant losses to investors.

Company Profile

Upstart Holdings, Inc. operates a cloud-based artificial intelligence lending platform in the United States. The company's platform facilitates unsecured personal loans, small dollar loans, auto refinance and retail loans, auto secured personal loans, and home equity lines of credit, using proprietary AI models to assess borrower risk through a process the company calls "risk separation."

Class Period

May 14, 2025 – November 4, 2025, both dates inclusive.

Investors who purchased or acquired Upstart Holdings, Inc. (UPST) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

Allegations

The complaint alleges that throughout the Class Period, Upstart's senior leadership, CEO Dave Girouard, CFO Sanjay Datta, CTO Paul Gu, and CMO Chantal Rapport, aggressively promoted the capabilities of Model 22, the latest iteration of Upstart's AI underwriting system launched in early May 2025. Defendants portrayed Model 22 as a breakthrough that was driving substantially higher loan approval rates, improved conversion rates, and accelerating revenue growth. On the strength of these representations, Upstart raised its full-year 2025 revenue guidance twice during the Class Period, first in May to approximately $1.01 billion and then again in August to approximately $1.055 billion, including an increase of $70 million in expected fee revenue, citing improvements driven specifically by Model 22.

At Upstart's inaugural AI Day on May 14, 2025, the Individual Defendants highlighted the model's purported superiority over traditional underwriting, with investor presentations depicting how the company's proprietary AI purportedly drove higher approval rates than traditional underwriting models. During the second-quarter earnings call on August 5, 2025, Defendant Girouard attributed the company's growth "primarily" to Model 22, while Defendant Datta credited the model for improving contribution margins and take rates. Defendant Gu described Model 22's ability to identify "many, many small subtle relationships in the data" as the source of higher approval rates. The Q2 2025 Form 10-Q, certified by Defendants Girouard and Datta under the Sarbanes-Oxley Act, attributed substantial increases in transaction volume and conversion rates to "model improvements." According to the complaint, these statements created an increasingly optimistic picture of Upstart's trajectory that was disconnected from what defendants knew about Model 22's actual behavior.

The lawsuit alleges that defendants knew or recklessly disregarded that Model 22 frequently overreacted to negative macroeconomic signals in performing its risk-separation processes, resulting in overly conservative credit assessments that reduced loan approvals and conversion rates. Defendant Gu later admitted on the Q3 2025 earnings call that defendants had "knowingly" chosen to make the model "more conservative on the credit side in earlier parts of the quarter." The complaint further alleges that defendants' failure to disclose these material deficiencies in Model 22 violated Item 303 of SEC Regulation S-K, which required disclosure of known trends or uncertainties reasonably likely to have a material unfavorable impact on revenues. Meanwhile, during the Class Period, Defendant Girouard sold 208,335 shares of Upstart stock for proceeds exceeding $13.5 million, Defendant Datta sold 26,985 shares for over $1.4 million, and Defendant Gu sold 5,000 shares for over $344,000.

The Truth Emerges

On November 4, 2025, after the market closed, Upstart reported third-quarter 2025 results that revealed the scope of Model 22's problems. The company reported Q3 revenue of $277 million, missing both its own guidance of approximately $280 million and consensus estimates by $2.62 million. Upstart also guided for Q4 2025 revenue of only $288 million, significantly below the $303.7 million consensus estimate, and cut its full-year 2025 revenue guidance to approximately $1.035 billion from the $1.055 billion it had projected just three months earlier. Expected full-year fee revenue was slashed to approximately $946 million from the prior outlook of approximately $990 million.

During the accompanying earnings call, the defendants directly attributed the shortfall to Model 22. Defendant Girouard acknowledged that the company's "risk models responded to macroeconomic signals they observed by moderately reducing approvals and increasing interest rates," driving a decline in conversion rates from 23.9% in Q2 to 20.6% in Q3. He conceded the model may have been "overreacting" and that the negative impact would continue into Q4. Defendant Gu went further, admitting that the model was "overly responsive" to changes and plagued by "measurement error," and that defendants had been "knowingly making a choice" to run the model more conservatively, a disclosure that directly contradicted the confident assurances made throughout the Class Period about Model 22's accuracy and its ability to drive sustained growth.

Market Reaction

Following these disclosures, Upstart's stock price fell $4.49 per share, or 9.71%, to close at $41.75 on November 5, 2025. The reaction was swift and severe across Wall Street: Morgan Stanley slashed its price target on UPST to $45 from $70, noting that Upstart needed to demonstrate its AI model and forecasting could "sufficiently adapt to UMI volatility." Goldman Sachs cut its target to $40 from $54, warning that "recent trends in volume are likely to underscore the limited forward visibility in the model." Citigroup reduced its target to $80 from $100, Bank of America cut to $71 from $81, Needham lowered to $56 from $82, and Stephens & Co. dropped to $40 from $55. American Banker reported that Upstart's stock had "plummeted" not because of poor profits, but because "its own AI model intentionally tightened the credit box, causing a miss on loan origination volume."

Next Steps

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

 

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Upstart, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Upstart, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
NUAI Shareholders - Lead Plaintiff Deadline: June 01, 2026

New Era Energy & Digital Class Action Lawsuit – NUAI

New Era Energy Class Action Summary

Company

New Era Energy & Digital, Inc. (NASDAQ: NUAI)

Lead Plaintiff Deadline

June 1, 2026

Class Period

November 6, 2024 – December 29, 2025

Stock Drop

December 12, 2025 – NUAI fell $0.25 (6.9%) to $3.35; December 29, 2025 – NUAI fell $1.87 (41%) to $2.69

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against New Era Energy & Digital, Inc. (NASDAQ: NUAI), its CEO Everett Willard Gray II, and former CFO Michael J. Rugen on behalf of investors who purchased New Era Energy securities between November 6, 2024 and December 29, 2025. The complaint alleges that defendants made materially false and misleading statements about the company's business operations, its progress on a flagship AI data center project, and its involvement in a fraudulent oil-and-gas well scheme in New Mexico. According to the complaint, when the truth emerged through a short-seller report on December 12, 2025, and a subsequent report revealing a New Mexico Attorney General lawsuit on December 29, 2025, NUAI shares suffered sharp declines, falling a combined 68% from the Class Period high of $8.50 per share and causing significant losses for investors.

Company Profile

New Era Energy & Digital, Inc., formerly known as New Era Helium Inc., is an oil and natural gas company that became publicly traded on the NASDAQ in December 2024 through a business combination with Roth CH Acquisition V Co. The company's primary revenue source is oil and gas wells located in Chaves County, New Mexico, operated by its subsidiary Solis Partners. During the Class Period, New Era Energy was also pursuing a strategic pivot into AI infrastructure, with its purported flagship venture being the Texas Critical Data Center, a reported large-scale AI and high-performance computing data center campus located in Ector County, Texas.

Class Period

November 6, 2024 – December 29, 2025, inclusive.

Investors who purchased or acquired New Era Energy & Digital, Inc. (NUAI) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

Allegations

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements about New Era Energy's business, financial condition, and prospects across multiple SEC filings and press releases. Beginning with the November 6, 2024 proxy statement soliciting shareholder approval of the company's business combination with Roth CH Acquisition V Co., through subsequent annual and quarterly reports and investor presentations, defendants allegedly misrepresented the company's financial results, including its asset retirement obligations, and overstated its progress toward developing its flagship Texas Critical Data Center project.

According to the complaint, defendants repeatedly touted "tangible progress across all fronts including engineering, permitting, regulatory filings, and land expansion" for the Texas Critical Data Center. An October 2025 press release highlighted "significant progress on obtaining air permits" and stated the company was "pursuing a minor source air permit." A November 2025 investor presentation filed with the SEC represented that "phase two" of the project, which included regulatory permitting, was "underway." The complaint alleges these statements were materially misleading because no permit applications had been submitted to any relevant state or federal agency.

The complaint further alleges that defendants concealed New Era Energy's involvement in what the New Mexico Attorney General would later characterize as a "fraudulent oil-and-gas scheme." Plaintiffs allege that CEO Gray orchestrated a pattern of transferring oil and gas wells among a network of related entities he controlled, including Remnant Oil, Acacia Resources, and Solis Partners, siphoning revenue from productive wells while strategically placing liability-bearing entities into bankruptcy to avoid plugging and remediation costs that New Mexico law required. Of NUAI's 406 gas wells, 346 were allegedly acquired from companies that went bankrupt operating those same wells, including 87 wells from Remnant Oil, a company Gray co-founded and led into bankruptcy in 2019 after hundreds of regulatory violations. Those 87 wells were reportedly transferred to Solis Partners, a New Era Energy subsidiary allegedly "dominated and controlled" by Gray, for a listed purchase price of just $10, while Acacia was left with the bulk of environmental liabilities.

The complaint alleges defendants knew or recklessly disregarded that the company's reported financial results, including its asset retirement obligations, were materially false and misleading because they failed to account for the true scope of the company's environmental liabilities and the fraudulent nature of the well transfers that generated the company's revenue. Throughout the Class Period, Gray served as CEO, and beginning June 2025, also assumed the role of CFO, a period during which, according to the Fuzzy Panda Research report quoted in the complaint, three of four independent board members and the prior CFO departed the company.

The Truth Emerges

On December 12, 2025, market research outlet Fuzzy Panda Research published a detailed report alleging that Gray had "a long history (~20 years) of incinerating value at oil & gas pink sheet companies" and that his companies declined an average of 98%. The report revealed that the company's AI data center pivot was a "fantasy," disclosing that searches of Texas, New Mexico, and federal government databases for the construction and environmental permits NUAI would need to build its data centers and power plants returned nothing, "not even an application[,]" despite the company's repeated representations to investors of significant permitting progress. The report also detailed Gray's alleged "playbook" of enriching insiders through related-party transactions, including converting related-party loans to equity and paying fees to friends and family.

On December 29, 2025, Hunterbrook Media reported that the New Mexico Attorney General had filed a sweeping enforcement lawsuit against New Era Energy, Solis Partners, and Gray, among others. The lawsuit accused the defendants of orchestrating a fraudulent scheme to "siphon revenue from wells that produce fossil fuels while abandoning environmental cleanup obligations." The Attorney General's complaint alleged a broader pattern of fraudulent transfers, self-dealing, and false statements to regulators, including the use of shell entities and strategic bankruptcies to evade responsibility. The complaint alleged that Gray formed Solis Partners specifically "to receive Remnant's best wells" while ensuring affiliated entities would be unable to meet their environmental obligations, leaving the state as the "plugger of last resort" for hundreds of abandoned wells.

Market Reaction

Following the publication of the Fuzzy Panda Research report on December 12, 2025, NUAI shares fell $0.25, or 6.9%, to close at $3.35 on unusually heavy trading volume, as the market absorbed the report's findings regarding the company's lack of permit applications and Gray's history of value destruction at prior companies.

The more severe decline came on December 29, 2025, when the Hunterbrook Media report revealed the New Mexico Attorney General's fraud lawsuit. NUAI shares plummeted $1.87, or 41%, to close at $2.69 per share on unusually heavy trading volume. The cumulative impact of the two corrective disclosures drove the stock approximately 68% below its Class Period high of $8.50 per share, reached on December 9, 2024, when the company became a public entity through its business combination with Roth CH Acquisition V Co.

Next Steps

●       The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●       The Court will then consider motion for class certification.

●       The Court will later consider a motion to dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in New Era Energy & Digital, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against New Era Energy & Digital, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
PINS Shareholders - Lead Plaintiff Deadline: May 29, 2026

Pinterest Class Action Lawsuit – PINS

Pinterest Class Action Summary

Company

Pinterest, Inc. (NYSE: PINS)

Lead Plaintiff Deadline

May 29, 2026

Class Period

February 7, 2025 – February 12, 2026

Stock Drop

November 5, 2025 – PINS fell $7.16 (21.76%) to $25.75; January 27, 2026 – PINS fell $2.49 (9.61%) to $23.41; February 13, 2026 – PINS fell $3.12 (16.83%) to $15.42

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Pinterest, Inc. (NYSE: PINS), CEO William Ready, and CFO Julia Brau Donnelly on behalf of investors who purchased or acquired Pinterest securities between February 7, 2025 and February 12, 2026. The complaint, filed in the United States District Court for the Northern District of California, alleges that defendants made materially false and misleading statements about Pinterest's ability to navigate macroeconomic headwinds, particularly the impact of U.S. tariffs on its largest advertising partners, while concealing that the company was experiencing or was likely to experience significant revenue declines that would ultimately necessitate a major corporate restructuring. As the truth emerged through a series of disappointing earnings reports and a restructuring announcement involving a nearly 15% workforce reduction, Pinterest's stock price suffered three significant declines, ultimately closing at $15.42 per share on February 13, 2026.

Company Profile

Pinterest is a visual social media platform where users organize content into themed "boards" that reflect their interests in various products and services. The company generates substantially all of its revenue from advertising, with a substantial portion coming from a small number of advertisers, particularly large retail and consumer packaged goods companies, who leverage Pinterest's platform to reach high-intent shoppers across the marketing funnel.

Class Period

February 7, 2025 – February 12, 2026, inclusive.

Investors who purchased or acquired Pinterest, Inc. (PINS) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

Allegations

The complaint alleges that throughout the Class Period, defendants consistently assured investors that Pinterest's business model was resilient, durable, and well-positioned to thrive regardless of the macroeconomic environment. Beginning with the company's Q4 2024 earnings call on February 6, 2025, CEO William Ready told investors that Pinterest's lower-funnel advertising innovations had "compounding effects over not just multiple quarters, but multiple years," while CFO Julia Donnelly described the business as "inherently profitable." Ready emphasized that Pinterest was "demonstrating that we can be a much larger portion of the overall ad market" and pointed to the company's deepening relationships with its largest, most sophisticated advertisers as evidence of sustainable growth.

According to the complaint, defendants continued making these representations even as the macroeconomic landscape deteriorated for Pinterest's core advertising partners. At a Morgan Stanley conference on March 6, 2025, Ready dismissed tariff-related concerns by asserting that "in any environment, people are still going to shop" and claiming Pinterest had "a real secular growth story" with fundamentals that "have just never been better." During the Q1 2025 earnings call on May 8, 2025, Ready declared that Pinterest's "strategy and consistent execution has made Pinterest more resilient than ever," while Donnelly stated that the company was "confident in our multiple revenue initiatives" and its "ability to compete effectively across a number of scenarios." When analysts specifically asked about tariff-exposed categories showing softness, Donnelly acknowledged only "small pockets of spend" had been impacted and reassured the market that "the fundamentals of our business remain strong." By the Q2 2025 earnings call on August 7, 2025, Donnelly identified retail as continuing to be a "sources of strength" and described the macroeconomic environment as "a relatively more constructive environment than feared."

The complaint alleges defendants knew or recklessly disregarded that these statements were materially false and misleading. Specifically, plaintiffs allege that Pinterest was experiencing or was likely to experience materially reduced revenues from its advertising partners, that defendants overstated the company's ability to manage the impact of U.S. tariffs on its largest retail advertisers, and that the severity of these headwinds was significant enough that Pinterest was facing an imminent need to restructure its operations. The complaint further alleges that during the Class Period, the Individual Defendants together sold approximately 421,903 shares of company stock for over $13.5 million in proceeds, with Ready selling 141,126 shares for over $4.3 million and Donnelly selling 280,777 shares for over $9.1 million, providing them with a financial motive to maintain the stock's artificially inflated price.

The Truth Emerges

The truth began to surface on November 4, 2025, when Pinterest reported its Q3 2025 financial results and issued Q4 revenue guidance with a midpoint of $1.325 billion, below the consensus expectation of $1.34 billion. During the earnings call, Donnelly acknowledged that Pinterest "faced pockets of moderating ad spend" as "larger U.S. retailers navigate tariff-related margin pressure in the current environment." This was a stark reversal from the confident assurances defendants had provided throughout the preceding months. Analyst reactions were swift: RBC Capital Markets cut its price target from $45 to $38, writing that "tariff-related weakness showed up for the first time" and would "reinforce PINS' lack of customer diversity for the bears"; Citi slashed its target from $50 to $38, identifying headwinds from "larger U.S. retailers moderating ad spend amid tariff-related margin pressures"; and HSBC reduced its target from $44.30 to $34.50. Yet even during this same earnings call, defendants continued to downplay the severity of the situation, with Donnelly insisting that "overall, we still feel really good about our mid- to high teens kind of revenue growth targets over the medium and long term."

The second corrective disclosure came on January 27, 2026, when Pinterest announced a board-approved global restructuring plan that included a reduction in force affecting nearly 15% of the company's workforce, along with office space reductions. The company estimated pre-tax restructuring charges of approximately $35 million to $45 million. Analysts viewed the announcement as a harbinger of further deterioration: RBC characterized it as "foreshadowing a revenue shortfall," Wells Fargo called it a "cautious early read on '26 revenue outlook," and HSBC bluntly stated, "We hate to say it, but it's not working."

The full extent of the damage became clear on February 12, 2026, when Pinterest reported Q4 2025 revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and provided Q1 2026 revenue guidance of $951 million to $971 million, well below the consensus estimate of $980.6 million. CEO Ready acknowledged an "exogenous shock this year related to tariffs, which are disproportionately affecting ad spend from our top retail advertisers" and admitted that the company's "higher mix of large retailers relative to some of our peers has resulted in us feeling more of an impact." CFO Donnelly conceded that "our largest retail advertisers created a more meaningful headwind than we expected" and warned that "we expect these headwinds will continue and may become slightly more pronounced in Q1."

Market Reaction

The series of corrective disclosures devastated Pinterest's stock price. Following the Q3 2025 earnings report on November 4, 2025, PINS fell $7.16 per share, or 21.76%, to close at $25.75 on November 5, 2025. When the company announced its restructuring plan on January 27, 2026, the stock declined an additional $2.49 per share, or 9.61%, to close at $23.41. The final blow came after the Q4 2025 earnings report on February 12, 2026, when PINS dropped $3.12 per share, or 16.83%, to close at $15.42 on February 13, 2026. HSBC again cut its price target, this time by 30% from $24.90 to $17.40, noting that the "combinations of decelerating revenues and margin pressure in the 1Q26 guidance still caught us off-guard." Over the course of these three corrective events, Pinterest shareholders suffered significant losses and damages as the stock price declined precipitously.

Next Steps

●               The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●               The Court will then consider motion for class certification.

●               The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Pinterest, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Pinterest, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
ALDX Shareholders - Lead Plaintiff Deadline: May 29, 2026

Aldeyra Therapeutics Class Action Lawsuit – ALDX

 

Aldeyra Therapeutics Class Action Summary

Company

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)

Lead Plaintiff Deadline

May 29, 2026

Class Period

November 3, 2023 – March 16, 2026

Stock Drop

March 17, 2026 – ALDX fell $2.99 (70.7%) to $1.24

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and certain of its senior officers on behalf of investors who purchased or acquired Aldeyra securities between November 3, 2023 and March 16, 2026. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the clinical trial results for reproxalap, the company's lead drug candidate for the treatment of dry eye disease. According to the lawsuit, defendants repeatedly touted reproxalap's "broad-based, rapid-onset activity" and "consistent" clinical results while concealing that the trial results were, in fact, inconsistent and that any positive findings were unreliable and not meaningful. When the U.S. Food and Drug Administration issued a Complete Response Letter on March 17, 2026, rejecting the drug's application and citing a "lack of substantial evidence" of efficacy, Aldeyra's stock price collapsed by approximately 70.7%, closing at $1.24 per share.

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. The company's lead product candidate, reproxalap, is a novel reactive aldehyde species (RASP) inhibitor that was under investigation as a treatment for dry eye disease.

Class Period

November 3, 2023 – March 16, 2026, inclusive.

Investors who purchased or acquired Aldeyra Therapeutics (ALDX) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

Allegations

The complaint alleges that Aldeyra Therapeutics and its senior officers, CEO Todd C. Brady, Head of Finance Michael Alferi, and former interim CFO Bruce M. Greenberg, made a series of materially false and misleading statements about the clinical trial performance of reproxalap, the company's flagship drug candidate. In SEC filings spanning the entire Class Period, defendants consistently represented that reproxalap had "demonstrated broad-based, rapid-onset activity and consistent safety across a number of Phase 2 and Phase 3 clinical trials" and that it had shown "consistent statistically significant and clinically relevant activity across a variety of symptoms and signs, occurring as early as within minutes of dosing."

These representations appeared in the company's quarterly report for the third quarter of 2023, filed November 3, 2023, and were signed by Brady and Greenberg. Substantially identical language was repeated in the annual reports for fiscal years 2023, 2024, and 2025, filed on March 7, 2024, February 28, 2025, and February 27, 2026, respectively. The fiscal year 2023 report was signed by Brady and Greenberg, while the fiscal year 2024 and 2025 reports were signed by Brady and Alferi, who assumed the principal financial officer role on August 31, 2024.

According to the complaint, these statements were materially false and misleading because the clinical trial results for reproxalap were not consistent across studies. The complaint alleges that this inconsistency rendered the positive findings defendants highlighted unreliable and not meaningful, a reality defendants knew or recklessly disregarded. By repeatedly characterizing reproxalap's trial data as demonstrating consistent efficacy, defendants allegedly concealed the fundamental weakness in the clinical evidence supporting the drug's viability, artificially inflating the price of Aldeyra securities throughout the Class Period.

The Truth Emerges

On March 17, 2026, before the market opened, Aldeyra disclosed in a Form 8-K filing that the company had received a Complete Response Letter from the FDA, a formal rejection of its drug application. The Complete Response Letter was devastating in its assessment: the FDA stated there was "a lack of substantial evidence" that reproxalap "will have the effect it purports or is represented to have" and that "the application has failed to demonstrate efficacy in adequate and well controlled studies in the treatment of signs and symptoms of dry eye disease."

Critically, the FDA's letter directly contradicted the core of defendants' years-long representations to investors. The agency stated that "the inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings" and that "the totality of evidence from the completed clinical trials does not support the effectiveness of the product." The complaint alleges that FDA's characterization of the trial results as inconsistent confirmed that the confident language about consistent activity in the company's SEC filings had been materially misleading.

Market Reaction

The market's response to the FDA's Complete Response Letter was swift and severe. On March 17, 2026, ALDX shares plummeted $2.99, or approximately 70.7%, to close at just $1.24 per share. The magnitude of the decline reflects the degree to which the market had relied on defendants' repeated assurances about the consistency and significance of reproxalap's clinical data, assurances that the FDA's letter revealed to be materially misleading.

Next Steps

●              The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●              The Court will then consider motion for class certification.

●              The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Aldeyra Therapeutics, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Aldeyra Therapeutics, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
GOSS Shareholders - Lead Plaintiff Deadline: June 01, 2026

Gossamer Bio, Inc. Class Action Lawsuit - GOSS

 

Gossamer Bio Class Action Summary

Company

Gossamer Bio, Inc. (NASDAQ: GOSS)

Lead Plaintiff Deadline

June 1, 2026

Class Period

June 16, 2025 – February 20, 2026

Stock Drop

February 23, 2026 – GOSS fell $1.71 (over 80%) to $0.42

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and its CEO Faheem Hasnain on behalf of investors who purchased or acquired Gossamer Bio securities between June 16, 2025, and February 20, 2026. The complaint, filed by Levi & Korsinsky, LLP on behalf of plaintiff Daniel Kinnamon in the United States District Court for the Southern District of California, alleges that defendants made materially false and misleading statements regarding the design and prospects of the Company's Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH). Specifically, the lawsuit claims defendants failed to disclose critical trial design issues at the study's Latin American clinical sites, where a heavily-treated, lower-risk patient population performed unusually well on placebo, ultimately causing the study to miss its primary endpoint. When Gossamer Bio disclosed topline results on February 23, 2026, the stock price collapsed from $2.13 to $0.42 per share, a decline of over 80% in a single trading day.

Company Profile

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension associated with interstitial lung disease. The Company is headquartered in San Diego, California, and its common stock trades on the NASDAQ under the ticker symbol GOSS.

Class Period

June 16, 2025 – February 20, 2026, inclusive.

Investors who purchased or acquired Gossamer Bio, Inc. (GOSS) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

GOSS-Infographic-Image.png

Allegations

The complaint alleges that throughout the Class Period, Gossamer Bio and its CEO Faheem Hasnain projected confidence in the Phase 3 PROSERA study, a registrational trial evaluating seralutinib's ability to improve six-minute walk distance (6MWD) in PAH patients at Week 24. Beginning with a June 16, 2025 press release announcing the completion of PROSERA enrollment, Hasnain told investors the Company had "focused on selecting a patient population that aligns closely with the study's objectives," stating that based on preliminary baseline characteristics, "we firmly believe that we have accomplished this patient selection goal." This set the tone for a series of statements that the complaint alleges painted an overwhelmingly positive picture of PROSERA's trajectory while concealing known deficiencies in the trial's design.

On August 5, 2025, Hasnain reinforced this narrative, describing the upcoming PROSERA readout as "the foundation" of a potential multi-billion-dollar franchise and expressing "conviction around the strength of the science." He told investors the team was "executing the PROSERA Study with discipline and operational excellence" and looked forward to sharing topline results in February. On November 5, 2025, Hasnain again highlighted the Company's progress, stating Gossamer was "progressing through the final stages of the PROSERA Phase 3 Study" and calling it "a pivotal moment."

According to the complaint, these statements were materially false and misleading because defendants knew or recklessly disregarded that patients enrolled at the Latin American clinical sites were largely heavily-treated and lower-risk, a population that would perform particularly well on placebo. As the drug's sponsor, defendants had access to non-public information about the trial's design, clinical site selection, and the protocol issues that posed acute risks to the study meeting its primary endpoint. The complaint alleges defendants constructed a narrative that PROSERA would succeed while failing to disclose the specific vulnerabilities in the Latin American testing sites that ultimately undermined the trial's statistical outcome.

The Truth Emerges

On February 23, 2026, Gossamer Bio published a press release and hosted a Special Call revealing that the Phase 3 PROSERA study had failed to meet its primary endpoint. While seralutinib showed a +28.2 meter improvement in 6MWD from baseline compared to +13.5 meters for placebo, the placebo-adjusted gain of +13.3 meters carried a p-value of 0.0320, failing to clear the prespecified 0.025 alpha threshold required for statistical significance. CEO Hasnain acknowledged the Company had "narrowly missed the stringent prespecified statistical threshold," while Chief Medical Officer Richard Aranda disclosed that "the placebo arm showed a larger improvement that is often seen in many other Phase III PH trials" and that "in other regions, particularly Latin America, outsized placebo improvements materially compressed the pool treatment difference."

During the question-and-answer session, COO and CFO Bryan Giraudo provided further detail that directly contradicted the Company's prior optimism. He disclosed that Gossamer had made "a significant investment in Latin America" expecting it to be the study's best-performing geography based on results from the STELLAR study for sotatercept, but instead found "an almost parity between the placebo rate and the treatment rate" in the region, a result he called "extremely, extremely disturbing." He acknowledged the Company was "still early in the investigation of what happened in Latin America." These revelations stood in stark contrast to defendants' prior statements, which the complaint alleges never mentioned any trial design concerns regarding the Latin American sites. Analyst reports following the disclosure confirmed the significance: Oppenheimer characterized the Latin American anomaly as "a trial execution issue, not a drug effect issue" and suggested the irregularity pointed to "human measurement error during 6MWD lap counting," while Wedbush downgraded Gossamer to Neutral and slashed its price target from $6 to $1.

Market Reaction

The market response to PROSERA's failure was immediate and severe. On February 23, 2026, Gossamer Bio's stock price plummeted from a closing price of $2.13 per share on February 20, 2026, to just $0.42 per share, a decline of over 80% in a single trading day. The over 80% decline reflected the market's reaction to learning that the Phase 3 PROSERA study had missed its primary endpoint due to trial design defects in Latin America that defendants had never disclosed during the Class Period.

Next Steps

●        The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●        The Court will then consider motion for class certification.

●        The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Gossamer Bio, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Gossamer Bio, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Alight, Inc. Class Action Lawsuit – ALIT

Introduction to Alight, Inc. (ALIT) Securities Class Action Lawsuit

The Alight Inc lawsuit is a federal securities class action filed by plaintiff Jeremy McCarty against Alight, Inc., former CEO David D. Guilmette, and former CFO Jeremy J. Heaton. The complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 by disseminating materially misleading business information about the Company's growth trajectory, execution capabilities, and the sustainability of its newly initiated quarterly dividend. According to the complaint, these misstatements artificially inflated ALIT's stock price during a class period that saw the stock lose approximately 90% of its value.

At the heart of this Alight shareholder lawsuit, according to the complaint, is a stark contrast: management repeatedly assured investors that Alight had the commercial team, pipeline strength, and operational discipline to return to profitable growth, while the Company allegedly was not equipped to execute on those promises without significantly higher compensation and incentive spending. According to the complaint, that alleged execution gap became more apparent on February 19, 2026, when new management disclosed additional operational shortfalls, increased compensation expense, and the cancellation of the dividend that prior management had described as a ‘commitment’ to shareholders. The lawsuit seeks to recover damages on behalf of all investors who purchased Alight common stock at artificially inflated prices during the Class Period.

Alight, Inc. (ALIT) Securities Lawsuit Case Details

Case Name: McCarty v. Alight, Inc. et al.

Case No.: 1:26-cv-02924

Jurisdiction: U.S. District Court, Northern District of Illinois

Filed on: March 16, 2026

Alight, Inc. (ALIT) Company Profile

According to the complaint, Alight, Inc. is a Delaware corporation headquartered in Chicago, Illinois. The Company is predominantly an employee benefits solutions provider that delivers technology-enabled services through the Alight Worklife cloud engagement platform. The platform offers integrated benefits administration, healthcare navigation, financial wellbeing, absence management, and retiree healthcare while providing employers with actionable insights through data, analytics, and AI. During the Class Period, Alight's common stock traded on the New York Stock Exchange under the ticker "ALIT."

Alight, Inc. (ALIT) Securities Lawsuit Class Period

The Class Period runs from November 12, 2024, to February 18, 2026.

According to the complaint, the period begins on the date Defendant Guilmette first presented his vision for Alight's future growth, announced the new quarterly dividend, and touted the Company's commercial momentum during the Q3 fiscal 2024 earnings call. The period ends the day before the final corrective disclosure on February 19, 2026, when Alight's new management revealed the full extent of the execution failures, earnings shortfall, and dividend cancellation.

ALIT-Infographic-Image.png

Allegations in the Alight, Inc. (ALIT) Securities Class Action Lawsuit

The ALIT securities fraud class action traces a pattern of optimistic statements followed by repeated disappointments across five quarterly reporting periods.

November 12, 2024: The complaint alleges that CEO Guilmette used Alight's Q3 fiscal 2024 earnings call to paint a rosy picture of the Company's future. He highlighted his 40-plus years of industry experience and declared: "We are the best in the industry at all facets of this business, from digital through managing benefits complexity." He announced a $0.04 per share quarterly dividend, calling it a reflection of the Company's "commitment and shareholder feedback to consistently return capital via dividends and share repurchases over the long term." CFO Heaton echoed that the dividend signified their "commitment to a consistent return of capital."

February 20, 2025: The lawsuit alleges that Defendants issued fiscal 2025 guidance projecting revenue of $2,318 million to $2,388 million and adjusted EBITDA of $620 million to $645 million. Guilmette stated that "our operating trends today are vastly improved with full-year 2024 retention rates up 8 points compared to the prior year." Heaton projected ARR bookings of $130 million to $145 million, claiming the Company benefited from "a strong pipeline."

March 20, 2025: At Investor Day, Defendants set mid-term targets including 4% to 6% total annual revenue growth by 2027, approximately 30% adjusted EBITDA margin by 2027, and cumulative free cash flow of approximately $1 billion between 2025 and 2027. Guilmette asserted: "Our current assets and our current capabilities position us for commercial success."

May 8, 2025: Defendants reaffirmed fiscal 2025 guidance. When asked about macroeconomic impacts on deal cycles, Guilmette stated: "We've not really seen any material shift in the buying patterns to date." The complaint alleges these statements were false because Alight's sales team was not equipped to execute in accordance with management's expectations.

August 5, 2025 (First Partial Corrective Disclosure): The complaint alleges that on this date, Defendants revealed disappointing Q2 results and cut revenue guidance by approximately $47 million at the midpoint. Guilmette acknowledged that "our commercial execution to get deals across the line has not been sufficient" and that ARR bookings "was not at the level we expected." The Company also disclosed a $983 million non-cash goodwill impairment charge. The lawsuit alleges investors reacted immediately to this revelation.

Despite the August 5 disclosures, the complaint alleges Defendants continued misleading investors by expressing confidence in updated targets while failing to disclose the full extent of execution difficulties.

November 5, 2025: Alight cut guidance again, reducing revenue expectations to $2,252 million to $2,282 million and adjusted EBITDA to $595 million to $620 million. A second goodwill impairment charge of $1,338 million was recorded. Both Individual Defendants departed the Company during Q4 2025: Guilmette's exit was announced November 24, 2025 (effective December 31, 2025), and Heaton's was announced December 18, 2025 (effective January 9, 2026). The complaint alleges both were effectively forced out due to the issues underlying the lawsuit.

The Truth Emerges

On February 19, 2026, Alight’s new CEO, Rohit Verma, disclosed additional details about the Company’s 2025 underperformance that, according to the complaint, revealed the scope of the execution issues previously not fully disclosed to investors. During the Alight earnings miss February 2026 call, Verma stated plainly: "In 2025, we did not meet our internal financial targets and new bookings and renewals did not meet our expectations, leading us to miss our forecast to the market." He attributed the underperformance squarely to an execution problem, stating: "This is a change in the execution of the company. So the biggest piece that we need to tighten is around execution."

The financial results confirmed the damage. Full-year 2025 revenue came in at $2,262 million, a 3.0% decline. Project revenue fell 22% for the year. Adjusted EBITDA for Q4 was $178 million versus $217 million in the prior year period, adversely impacted by approximately $45 million in increased compensation expense that new management characterized as "critical to executing on our priorities." The Company also recognized an additional $803 million non-cash goodwill impairment charge, bringing the full-year total to $3,124 million. Perhaps most strikingly, the Company cancelled the quarterly dividend that Defendants had instituted barely a year earlier, stating there were "more efficient capital allocation activities" for driving long-term shareholder value.

Market Reaction

According to the complaint, the ALIT stock price collapse occurred across two corrective events. On August 5, 2025, ALIT fell from $5.13 to $4.19 per share, a decline of approximately 18.32% in a single trading day. On February 19, 2026, the stock fell from $1.31 to $0.81 per share, a decline of nearly 38%. Over the full Class Period, the stock had fallen approximately $6.85, or nearly 90%. The complaint notes that analysts at JP Morgan, UBS, D.A. Davidson, and Citi lowered their price targets following these disclosures. Citi called the situation "the classic definition of a value trap" and slashed its target to $1.00.

Next Steps

●        The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●        The Court will then consider motion for class certification.

●        The Court will later consider a Motion to Dismiss.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Alight, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Alight, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
STLA Shareholders - Lead Plaintiff Deadline: June 08, 2026

Stellantis N.V. Class Action Lawsuit – STLA

 

Stellantis Class Action Summary

Company

Stellantis N.V. (NYSE: STLA)

Lead Plaintiff Deadline

June 8, 2026

Class Period

February 26, 2025 – February 5, 2026

Stock Drop

February 6, 2026 – STLA fell $2.26 (23.69%) to $7.28

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Stellantis N.V. (NYSE: STLA) and several of its senior executives by plaintiff Christopher Harman, represented by Levi & Korsinsky, LLP. The lawsuit covers investors who purchased Stellantis common stock between February 26, 2025, and February 5, 2026, alleging that defendants made materially false and misleading statements about the company's earnings growth potential, its opportunity in the electrification market, and the scale of restructuring charges required to realign its business with actual customer demand. On February 6, 2026, Stellantis announced approximately €22.2 billion in charges alongside a comprehensive "reset" of its business, revealing that its prior confidence in battery-electric vehicle adoption had been fundamentally misplaced. In response, Stellantis stock fell from $9.54 to $7.28 per share in a single trading day, a decline of approximately 23.69%.

Company Profile

Stellantis N.V. is a global automobile designer, engineer, manufacturer, and distributor operating under numerous brands including Jeep, Ram Trucks, Chrysler, Dodge, Fiat, Peugeot, Citroën, Alfa Romeo, Maserati, and Opel. The company also provides financing, leasing, rental services, and after-market parts businesses across multiple geographic regions.

Class Period

February 26, 2025 – February 5, 2026, inclusive.

Investors who purchased or acquired Stellantis N.V. (STLA) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

STLA-Infographic-Image.png

Allegations

The complaint alleges that beginning on February 26, 2025, when Stellantis reported its fourth quarter and full year 2024 results, defendants painted a consistently optimistic picture of the company's electrification strategy and earnings trajectory. Executive Chairman John Elkann told investors that "electrification is growing" and that Stellantis was "very well equipped for the world to come," while then-CFO Douglas Ostermann outlined expectations for adjusted operating income margins ramping to mid-to-high single digits in North America's second half and significant improvement in Europe. According to the complaint, these statements failed to disclose that Stellantis was not truly positioned to grow its adjusted operating income as forecasted and that its confidence in the pace of electric vehicle adoption was fundamentally disconnected from actual customer demand.

As 2025 progressed, defendants allegedly continued reinforcing this narrative even as warning signs mounted. Stellantis suspended its full-year guidance in April 2025 citing tariff uncertainties, and its first-half results revealed AOI margins of just 0.7% alongside €3.3 billion in restructuring charges. When asked about the potential for additional charges in the second half, Ostermann acknowledged they "could see other strategic shifts that could lead to onetime charges" but characterized the outlook in measured terms. By October 2025, new CFO Joao Laranjo similarly told investors that any project cancellations "could have a cash impact" but that the company "would expect to have limited cash impact in '25." The complaint alleges these disclosures materially understated the severity of what defendants knew or recklessly disregarded about the restructuring required.

The complaint further points to an internal contradiction in defendants' messaging. Even as CEO Antonio Filosa acknowledged in mid-2025 that Stellantis was "correcting some initial all-in BEV powertrain decisions" because prior assumptions about 50% U.S. BEV penetration by 2030 had proven wrong, actual penetration was below 6%, defendants continued to guide investors toward low-single-digit AOI margins for the second half and sequential improvement in all key performance indicators. According to plaintiffs, defendants were aware that the gap between Stellantis' BEV-centric strategy and real customer preferences would necessitate charges of a magnitude far beyond anything signaled to the market, yet they repeatedly minimized these risks while the company's stock traded at artificially inflated prices.

The Truth Emerges

On February 6, 2026, Stellantis disclosed the full scope of its strategic miscalculation. The company announced approximately €22.2 billion in charges, including €6.5 billion in cash payments expected over the following four years, as part of what it called a "decisive reset" of its business. Of these charges, €14.7 billion related directly to realigning product plans with customer preferences, encompassing €2.9 billion in write-offs of cancelled products and €6.0 billion in impairments of BEV platforms due to "substantially reduced volume and profitability expectations." Another €2.1 billion addressed the need to resize the company's electric vehicle supply chain, while €5.4 billion covered warranty provision adjustments driven by quality deterioration and other operational charges. CEO Filosa stated the charges "largely reflect the cost of over-estimating the pace of the energy transition that distanced us from many car buyers' real-world needs, means and desires."

The disclosure also revealed that Stellantis had missed even its already-reduced second-half guidance, with AOI finishing below the guided low-single-digit range. Stellantis announced it would not pay a dividend in 2026 and authorized the issuance of up to €5 billion in hybrid bonds. Analysts reacted with shock at the scale of the writedown. Deutsche Bank noted that "the size of the charges taken and the cash relevant portion of it which is far above market expectations," while Morningstar described the magnitude as "a surprise, particularly the €6 billion platform impairments, given the supposed flexibility of Stellantis' multi-energy architecture to support different powertrains." The gap between what defendants had prepared the market for, the possibility of incremental charges with "limited" cash impact, and the €22.2 billion reality underscored the degree to which investors had been kept in the dark about the full extent of Stellantis' strategic and operational problems.

Market Reaction

Stellantis stock suffered an immediate and severe decline following the February 6, 2026 disclosure. Shares fell from a closing price of $9.54 on February 5, 2026, to $7.28 on February 6, 2026, a single-day drop of approximately $2.26 per share, or 23.69%. The magnitude of the sell-off reflected the market's recognition that the €22.2 billion in charges, the earnings miss against previously guided benchmarks, and the suspension of the dividend collectively represented a far more dire situation than defendants had communicated throughout the Class Period. Multiple analysts cut their price targets in the wake of the announcement, with Deutsche Bank resetting its target and Morningstar reducing its estimate by approximately 12.86%.

Next Steps

●        The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●        The Court will then consider motion for class certification.

●        The Court will later consider a motion to dismiss.

 

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Stellantis N.V. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Stellantis N.V. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1
MEDP Shareholders - Lead Plaintiff Deadline: June 08, 2026

Medpace Holdings, Inc. Class Action Lawsuit – MEDP

Medpace Class Action Summary

Company

Medpace Holdings Inc. (NASDAQ: MEDP)

Lead Plaintiff Deadline

June 8, 2026

Class Period

April 22, 2025 – February 9, 2026

Stock Drop

February 10, 2026 – MEDP fell $84.30 (15.9%) to $446.05

Lawsuit Type

Securities Class Action

Introduction

A securities class action lawsuit has been filed against Medpace Holdings Inc. (NASDAQ: MEDP), its Chairman and CEO August James Troendle, President Jesse J. Geiger, and CFO Kevin M. Brady in the United States District Court for the Southern District of Ohio. The lawsuit, filed by plaintiff Jan Durbin and represented by Strauss Troy Co., LPA and Levi & Korsinsky, LLP, covers a Class Period from April 22, 2025 through February 9, 2026. The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding Medpace's projected book-to-bill ratio and backlog cancellation rates, repeatedly assuring investors that a 1.15 book-to-bill ratio for the second half of fiscal year 2025 was reasonable and achievable while concealing the true state of the Company's cancellation trends. When Medpace reported a fourth quarter 2025 book-to-bill ratio of just 1.04 on February 9, 2026, well below the 1.15 guidance, the Company's stock price plummeted from $530.35 to $446.05 per share, a decline of more than 15.9%, causing significant losses to investors who had purchased shares at artificially inflated prices.

Company Profile

Medpace Holdings Inc. is a clinical contract research organization (CRO) focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The Company's operating model centers on providing full-service Phase I-IV clinical development services, with its principal executive offices located in Cincinnati, Ohio.

Class Period

April 22, 2025 – February 9, 2026, inclusive.

Investors who purchased or acquired Medpace Holdings Inc. (MEDP) securities during the Class Period may be entitled to seek recovery under the federal securities laws.

 

MEDP-Infographic-Image.png

Allegations

The complaint alleges that Medpace's senior leadership engaged in a sustained campaign of misleading statements about the Company's business outlook, centering on the book-to-bill ratio, a key metric that measures new business awards relative to revenue and signals future growth trajectory. Beginning with the first quarter 2025 earnings call on April 22, 2025, CEO Troendle told analysts that despite a book-to-bill of just 0.9 for Q1, there were "paths toward getting to 1.15" in the back half of the year, characterizing a downside scenario as "somewhere around 1." According to plaintiffs, these projections were made without adequate basis given the Company's deteriorating cancellation trends.

The alleged misrepresentations intensified during the second quarter earnings call on July 22, 2025, when Troendle stated the Company saw "strong potential for book-to-bills returning to above 1.15x in Q3" and described cancellations as "very well behaved[,]" noting they were "toward the lower end of expectations or usual history." The complaint alleges Troendle specifically reassured investors that the Company's challenges were "driven by cancellations, not weak business" and that the underlying business environment was "pretty okay," framing the cancellation issue as an anomaly rather than a systemic risk. Medpace raised its revenue guidance by $280 million at the midpoint during this call, further reinforcing the optimistic outlook.

By the third quarter earnings call on October 23, 2025, Medpace reported a strong 1.20 book-to-bill and record net bookings, with Troendle again describing cancellations as "well behaved." The complaint alleges that when an analyst directly asked about expectations for fourth quarter book-to-bill, Troendle reiterated that 1.15 "looks reasonable" as a Q4 target. CFO Brady described the Company's performance as "pretty broad-based" and not "isolated to a handful of studies," while Troendle acknowledged the pre-backlog was "over-indexed in metabolic" but characterized this as consistent with current trends rather than a concentration risk.

The complaint alleges defendants knew or recklessly disregarded that the therapeutic segments driving growth, particularly metabolic trials, carried elevated cancellation risk that threatened the 1.15 target. According to plaintiffs, defendants had actual knowledge of or access to non-public information about the Company's pre-backlog composition and how cancellation patterns would translate to the book-to-bill ratio, yet repeatedly conveyed an unjustifiably optimistic projection to the market.

The Truth Emerges

On February 9, 2026, after the market closed, Medpace issued a press release reporting fourth quarter 2025 results that revealed a book-to-bill ratio of just 1.04, significantly below the 1.15 guidance defendants had maintained throughout the Class Period. During the February 10, 2026 earnings call, CEO Troendle acknowledged that "cancellations were elevated again in Q4" and that "backlog cancellations in absolute and percent terms were the highest they've been in over a year," directly contradicting his repeated prior assurances that cancellations were "well behaved" and manageable. Troendle conceded that the cancellations were "a little bit skewed towards metabolic[,]" the very area that CFO Brady had previously assured investors was part of a "broad-based" growth profile rather than a concentrated risk.

The disclosures drew immediate and pointed reactions from analysts who had relied on defendants' prior guidance. Baird Equity Research published a report titled "Expect Shares Under Pressure Tomorrow," highlighting the bookings miss. Truist lowered its price target from $555 to $539, noting that "the sequential decline in B2B and the increase in cancellations came as a surprise to many investors" and characterizing the results as reflective of "the inherent volatility in its business model given its concentrated exposure, as well as the limited visibility associated with its pre-backlog." The analyst commentary underscores the degree to which the market had relied on defendants' repeated assurances about both the 1.15 target and the manageability of cancellation risk.

Market Reaction

The market reaction to Medpace's fourth quarter 2025 disclosure was swift and severe. From a closing price of $530.35 per share on February 9, 2026, MEDP shares plunged to $446.05 per share on February 10, 2026, a single-day decline of more than 15.9%, representing a loss of $84.30 per share. The magnitude of the drop reflects how deeply the market had priced in defendants' repeated guidance of a 1.15 book-to-bill ratio, and the shock of learning that backlog cancellations had reached their highest levels in over a year at the very moment defendants had projected confidence and stability.

Next Steps

●        The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.

●        The Court will then consider motion for class certification.

●        The Court will later consider a motion to dismiss.

 

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Medpace Holdings, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Medpace Holdings, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Seritage Growth Properties Class Action Lawsuit: SRG Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Seritage Growth Properties (NYSE: SRG) concerning potential violations of the federal securities laws.

Seritage reported its first quarter earnings on May 10, 2024. Based on the Company’s financial results, shares fell by more than 27% on May 13, 2024. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

If you suffered a loss on your Seritage securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Seritage Growth Properties which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Seritage Growth Properties. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Ziff Davis, Inc. Class Action Lawsuit: ZD Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Ziff Davis, Inc. (NASDAQ: ZD) concerning potential violations of the federal securities laws.

Throughout 2025, Ziff Davis highlighted adjusted EBITDA and adjusted diluted EPS as key performance measures in its earnings presentations and calls. On the Q2 2025 earnings call on August 8, 2025, CFO Bret Richter reported adjusted diluted EPS of $1.24, noting that the figure reflected higher adjusted EBITDA and lower diluted shares outstanding. The Company's GAAP results, which included foreign-exchange-related losses and other items excluded from adjusted figures, painted a different picture of the Company's financial health -- a gap investors could not easily see from the headline numbers presented each quarter. When Q4 2025 results were released, reported revenue declined 1.5% year-over-year to $406.7 million and adjusted EPS missed consensus and internal projections. The stock fell double digits in a single session.

If you suffered a loss on your Ziff Davis, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Ziff Davis, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Ziff Davis, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Surgery Partners, Inc. Class Action Lawsuit: SGRY Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Surgery Partners, Inc. (NASDAQ: SGRY) concerning potential violations of the federal securities laws.

Surgery Partners issued a press release on November 10, 2025, announcing its financial results for the third quarter of 2025 and held an earnings call to discuss the same. The Company lowered its full-year revenue guidance to a range of $3.275 billion to $3.3 billion, and its adjusted EBITDA guidance to a range of $535 million to $540 million. Surgery Partners' management attributed the guidance revision to timing delays in capital deployment, lost earnings from ambulatory surgical center divestitures, and a cautious stance on commercial payer mix and volume in the fourth quarter. Following this news, Surgery Partners' stock price fell over 25% on November 10, 2025.

If you suffered a loss on your Surgery Partners, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Surgery Partners, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Surgery Partners, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Agios Pharmaceuticals, Inc. Class Action Lawsuit: AGIO Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) concerning potential violations of the federal securities laws.

On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease. While the trial met one of its primary endpoints, it failed to achieve in the other, falling shy of a statistically significant improvement in annualized rate of pain (“pain crises”). Additionally, the “key secondary endpoint of change from baseline in PROMIS Fatigue was not met.” Following this news, Agios’ stock price fell by $22.33 per share to open at $23.16 per share.

If you suffered a loss on your Agios Pharmaceuticals, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Agios Pharmaceuticals, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Agios Pharmaceuticals, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Molina Healthcare, Inc. Class Action Lawsuit: MOH Lawsuit Sign Up Form

Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Molina Healthcare, Inc. (NYSE: MOH) securities.

If you suffered a loss on your Molina investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: Feb 05 2025 - Jul 23 2025

CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed: (1) material, adverse facts concerning the Company’s “medical cost trend assumptions;” (2) that Molina was experiencing a “dislocation between premium rates and medical cost trend;” (3) that Molina’s near term growth was dependent on a lack of “utilization of behavioral health, pharmacy, and inpatient and outpatient services;” (4) as a result of the foregoing, Molina’s financial guidance for fiscal year 2025 was substantially likely to be cut; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis Molina's stock price dropped following this news.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Molina Healthcare, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Molina Healthcare, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Zions Bancorporation, National Association Class Action Lawsuit: ZION Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Zions Bancorporation, National Association (NASDAQ: ZION) concerning potential violations of the federal securities laws.

Bloomberg published a report on October 16, 2025, titled, “Zions, Western Alliance Banks Disclose Bad Loans Tied to Alleged Fraud.” The article revealed that Zions and another regional bank suffered losses tied to fraudulent loans made to funds investing in distressed commercial real estate. Following this news, Zions’ stock price fell over 13% that same day.

If you suffered a loss on your Zions Bancorporation, National Association securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Zions Bancorporation, National Association which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Zions Bancorporation, National Association. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join MediaAlpha, Inc. Class Action Lawsuit: MAX Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into MediaAlpha, Inc. (NYSE: MAX) concerning potential violations of the federal securities laws.

On November 4, 2024, MediaAlpha disclosed receipt of a letter from the FTC, which stated that the FTC was “prepared to recommend the filing of a complaint against the Company” claiming that MediaAlpha falsely “represented itself as affiliated with government entities, made misleading claims (in particular regarding health insurance products and use of consumers’ personal information) and utilized deceptive advertising.” MediaAlpha’s stock fell over 27% following this news. The investigation concerns whether MediaAlpha and certain of its officers and/or directors have engaged in securities fraud.

If you suffered a loss on your MediaAlpha securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in MediaAlpha, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against MediaAlpha, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Mister Car Wash, Inc. Class Action Lawsuit: MCW Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Mister Car Wash, Inc. (NYSE: MCW) concerning potential violations of the federal securities laws.

MCW issued a press release announcing its fourth quarter and fiscal year 2023 financial results. Among other items, MCW reported revenue of $230.1 million, missing consensus estimates by $0.32 million. Following this news, on February 22, 2024, MCW’s stock price fell over 7%.

If you suffered a loss on your Mister Car Wash, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Mister Car Wash, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Mister Car Wash, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join World Acceptance Corporation Class Action Lawsuit: WRLD Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into World Acceptance Corporation (NASDAQ: WRLD) concerning potential violations of the federal securities laws.

On February 23, 2024, the Consumer Financial Protection Bureau announced that risks surrounding World Acceptance Corporation’s conduct warranted the need for federal supervision. following this news, on February 26, 2024, shares of World Acceptance Corporation dropped over 9%.

If you suffered a loss on your World Acceptance securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in World Acceptance Corporation which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against World Acceptance Corporation. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Banco Santander, S.A. Class Action Lawsuit: SAN Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Banco Santander, S.A. (NYSE: SAN) concerning potential violations of the federal securities laws.

A Financial Times article alleged Banco Santander was used by Iran to covertly move money around the world as part of a sanctions-evading scheme. Following this news, on February 5, 2024, shares of Banco Santander S.A. stock dropped over 5% in premarket trading.

If you suffered a loss on your Banco Santander securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Banco Santander, S.A. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Banco Santander, S.A. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Snap Inc. Class Action Lawsuit: SNAP Lawsuit Sign Up Form

Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Snap Inc. (NYSE: SNAP) securities.

If you suffered a loss on your Snap investment and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT: Feb 27 2019 - Feb 27 2024

CASE DETAILS: On Feb. 6, 2024, after announcing it would reduce its job force by 10%, Snap reported disappointing Q4 and FY 2023 financial results and disappointing guidance for its March quarter, again unable to prove that it can be profitable on a GAAP basis. Quarterly revenues came in at about $1.36 billion, just a 5% year-over-year increase and missing analysts' consensus. While the company said that its daily active user base grew 10% year-over-year to 414 million, that rate decelerated from prior quarters. One analyst reportedly observed "‘Snap has failed to show the market its ability to capitalize on resilient ad spending across different parts of the economy.'" Following this news, on February 7, 2024, Snap shares dropped over 5% during intraday trading.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Snap Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Snap Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join AN2 Therapeutics, Inc. Class Action Lawsuit: ANTX Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into AN2 Therapeutics, Inc. (NASDAQ: ANTX) concerning potential violations of the federal securities laws.

Before the market open on February 12, 2024, AN2 Therapeutics announced a pause in Phase 3 enrollment in its seamless Phase 2/3 clinical trial (EBO-301) evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. Following this news, shares of AN2 Therapeutics stock over 73% in premarket trading.

If you suffered a loss on your AN2 Therapeutics securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in AN2 Therapeutics, Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against AN2 Therapeutics, Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1

Join Repare Therapeutics Inc. Class Action Lawsuit: RPTX Lawsuit Sign Up Form

Levi & Korsinsky notifies investors that it has commenced an investigation into Repare Therapeutics Inc. (NASDAQ: RPTX) concerning potential violations of the federal securities laws.

Repare Therapeutics issued a press release, on February 12, 2024, "announc[ing] . . . that it will regain global development and commercialization rights to camonsertib (RP-3500), a potential best-in-class oral small molecule inhibitor of ATR (Ataxia-Telangiectasia and Rad3-related protein kinase), following termination of its collaboration agreement with Roche." The press release stated that "Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche's pipeline and evolving external factors." Following this news, on February 13, 2024, Repare's stock price fell over 15%.

If you suffered a loss on your Repare Therapeutics securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.

Step 1 of 3

Quick First Step

Please provide your address so we can contact you about your case if eligible.

1
1
1
1
1
1
Step 2 of 3

Add Your Transactions

Input your stock purchases and sales

Purchases

+ Additional Purchases

Sales

+ Additional Sales

Alternatively, you may upload your transactions below or e-mail them to [email protected]

1
1
1
1
1
1
Step 2 of 3

Certification of Plaintiff Pursuant to Federal Securities Laws

I, duly certify and say, as to the claims asserted under the federal securities laws, that:

  1. I have reviewed a complaint filed in the action.
  2. I did not purchase the security that is the subject of this action at the direction of plaintiff's counsel or in order to participate in this action.
  3. I am willing to serve as a representative party on behalf of the class, including providing testimony at deposition and trial, if necessary.
  4. My transaction(s) in Repare Therapeutics Inc. which are the subject of this litigation during the class period set forth in the complaint are set forth in the chart attached hereto.
  5. Within the last 3 years,
  6. I will not accept any payment for serving as a representative party on behalf of the class beyond the Plaintiff's pro rata share of any recovery, except as ordered or approved by the court, including any award for reasonable costs and expenses (including lost wages) directly relating to the representation of the class.

Are you US Citizen?

Clear

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

By your signature above, you confirm that have retained Levi & Korsinsky, LLP to represent you and the shareholder class as a lead plaintiff in the pending class action against Repare Therapeutics Inc. This representation will be on a contingency basis, meaning that Levi & Korsinsky will advance all expenses in the litigation and will only seek compensation and/or reimbursement of expenses if the firm obtains a recovery. Regardless of the result, we will never ask you to directly pay for any attorneys’ fees, expenses, or costs. Should we obtain a favorable result, we may ask the court to award us compensation and reimbursement of expenses to be paid by the defendants or as a portion of any class recovery. In exchange for our representation, you agree to cooperate as our client by providing, for example, relevant documents and deposition testimony, if necessary. During the course of this litigation, we may employ and/or work with other law firms, experts, and third-parties to successfully prosecute this action. If you are not appointed as the lead plaintiff or Levi & Korsinsky is not appointed as lead counsel, we will notify you of such decision at which time this representation will end unless otherwise extended by you and the firm. We look forward to working with you towards a successful resolution of this action.

1
1
1
1
1
1
Step 3 of 3

Upload Your Stock Tickers

Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.

✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure

1
1
1
1
1
1